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ABSTRACT 
EXOSOMES FROM EMBRYONIC STEM CELLS AS A PROPHYLACTIC  
VACCINE AGAINST LUNG CANCER 
 
Shuhan Meng 
April 20, 2020 
 
The antigenic similarity between embryos and tumors has raised the idea of 
using embryonic materials as a preventative vaccine against neoplastic disease. 
Indeed, a previous study reported that a vaccine comprised of allogeneic 
murine embryonic stem cells (ESCs) and murine fibroblasts expressing 
immune-stimulatory granulocyte macrophage-colony stimulating factor (GM-
CSF) successfully blocked the outgrowth of an implantable lung cancer (Lewis 
lung carcinoma; LLC) and lung tumors caused by a combination of a mutagen 
followed by chronic pulmonary inflammation. However, such a vaccine is 
obviously impractical for application to humans. The use of fibroblasts to 
produce GM-CSF is needlessly complicated, and intact live ESCs carry the 
hazard of generating embryomas/teratomas.  
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Here, we report the successful development of an alternative prophylactic 
vaccine comprised of exosomes/microvesicles derived from murine ESC line 
ES-D3 engineered to produce GM-CSF. The prophylactic potential of this 
exosome-based vaccine against implanted lung cancer (subcutaneous 
inoculation of LLC) was tested by immunizing mice with ESC-derived exosomes 
bearing GM-CSF (ES-exo/GM-CSF). Vaccination significantly slowed or 
blocked the outgrowth of LLC without any detectable side effects in liver 
function, kidney function and blood cell counts, whereas control exosomes 
lacking GM-CSF were ineffective against LLC. In an implanted lung tumor 
model, examination of tumor-infiltrating immune cells showed robust tumor-
reactive immune responses in mice vaccinated with the exosomes bearing GM-
CSF, including an increase in Th1 cytokine responses, CD8+ T effector 
responses and CD8+ T effector/T regulatory cell ratio.  
To further evaluate the efficacy of ES-exo/GM-CSF vaccination in 
preventing lung tumor development, we investigated an experimental 
metastasis model where syngeneic LLC cells were administered directly into 
the bloodstream of wild-type C57BL/6 mice through tail vein injection, primarily 
resulting in pulmonary metastases. Our studies indicate that vaccination with 
ES-exo/GM-CSF inhibited metastatic growth of lung tumors. Importantly, 
control exosomes without GM-CSF failed to provide little protection against 
metastasized pulmonary malignancies. The efficacy of ES-exo/GM-CSF 
vaccination was associated with a decrease in tumor-promoting T regulatory 
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cells, myeloid derived suppressor cells (MDSCs) and macrophages in tumor 
infiltrates as well as an increase in cytokine production from intratumoral CD8+ 
T cells.  
Since the pluripotency is one of the most specialized properties shared 
between ESCs and a subset of lung tumor cells, cancer stem cells (CSCs), we 
investigated the role of pluripotency of murine ESCs in prophylactic 
effectiveness of ESC-based vaccine. The pluripotency of murine ESCs was 
significantly reduced when they were differentiated into neuronal cells. The 
pluripotency of ESCs was essential for their anchorage-independent growth 
potential. Importantly, differentiation decreased the efficacy of ESCs against the 
outgrowth of implanted lung tumors. Furthermore, long-term cancer-preventive 
potential of ESC vaccine was also inhibited by differentiation. In summary, these 
data indicate the importance of pluripotency of ESCs in their prophylactic 
efficacy against lung cancer. 
While ESC-based vaccine has shown great potential, the antigens 
responsible for its prophylactic efficacy had not been identified yet. Since it is 
possible that the antibodies generated by ESC vaccine directly bind tumor cells 
and initiate antibody-dependent cellular cytotoxicity (ADCC), we employed a 
novel immunoproteomic strategy to gain a deep understanding of antigenicity 
of ESC-derived vaccine. We examined the comprehensive profiles of antigens 
specific for the antibodies induced by vaccines based on intact ES-D3 cells or 
exosomes of ES-D3 cells. Antigens shared by ES-D3 cells and lung tumor cells 
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were identified, among which lung tumor-associated keratin members 8, 16, 17 
are candidate antigens responsible for initiating anti-lung tumor immunity 
through ADCC.  
Overall, based on the antigenic similarities between embryos and lung 
tumors, we developed an effective lung cancer vaccine composed of ESC-
derived exosomes bearing GM-CSF. This vaccine was very effective in 
preventing both primary and metastasized lung tumors by evoking tumor-
specific immunity. Therefore, we conclude that a similar vaccine derived from 
GM-CSF-expressing human ESCs may be applicable to humans with 
increased risk of developing lung cancer, such as long-term smoking history, 
lung cancer family history, and carcinogen exposure. 
 
Key words: Exosomes, embryonic stem cells, immune-stimulatory granulocyte 
macrophage-colony stimulating factor, prophylactic vaccine, lung cancer
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CHAPTER I 
OVERVIEW 
 
1.1. Lung cancer therapy overview 
Worldwide, lung cancer is the most common cancer among men in terms of 
both incidence and mortality [1]. Among women, lung cancer has the third 
highest incidence and is the second after breast cancer in mortality. Current 
therapeutic strategies for lung cancer include surgery, chemotherapy, 
radiotherapy, and emerging immunotherapy. However, surgery can be only 
utilized at the very early stages of lung cancer. Additionally, patients must 
surpass pulmonary function benchmarks to qualify for surgery. Chemotherapy 
and radiotherapy usually serve as maintenance treatment after surgery or as 
first-line therapies for patients who are not eligible for surgery. Unfortunately, 
non-small cell lung carcinoma (NSCLC), the most prevalent type of lung cancer, 
is especially insensitive to chemotherapy or radiation therapy [2]. Most patients 
with NSCLC patients are at advanced stages at the time of diagnosis. As a 
result, the 5 years survival rate of patients with NSCLC is low [3].  
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Due to the limitation of conventional lung cancer treatments, more and 
more researchers are focusing on immunotherapy, which promotes the immune 
system to attack tumor cells either alone or combined with other 
chemotherapeutics. As a promising therapy to improve patient survival, lung 
cancer immunotherapy is generally categorized into 5 classes: nonspecific 
immune stimulation, T cell transfer, immune checkpoint inhibitors, antibody-
based therapy and cancer vaccines [4]. These therapeutic strategies for lung 
cancer are at various phases for clinical applications — some are approved to 
treat patients, whereas others are still under preclinical studies.  
Nonspecific immune stimulation functions by using immunostimulatory 
agents, such as interferon alpha (INF-) and certain interleukins, without 
targeting cancer cells specifically [4]. T cell transfer therapy is an 
immunotherapeutic strategy that engineers immune cells of patients to 
eliminate cancer specifically, including tumor-infiltrating lymphocytes (TIL) 
therapy and chimeric antigen receptor (CAR) T cell therapy [4]. Immune 
checkpoint inhibitors are designed to block the “off” signal from immune 
checkpoints, allowing activated T cells to attack neoplastic cells [5]. Among 
immune checkpoint inhibitors, antibodies specific for programmed cell death 
protein 1 (PD-1) (nivolumab and pembrolizumab) and programmed cell death 
protein ligand 1 (PD-L1) (atezolizumab) have been approved by the US Food 
and Drug Administration (FDA) to treat patients with NSCLC. Monoclonal 
antibodies against molecules involved in lung tumorigenesis have been used in 
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antibody-based therapy to directly kill lung neoplastic cells or deliver tumor-
killing agents to them [5]. The best known example of antibody-based therapy 
is cetuximab, a monoclonal antibody against the epidermal growth factor 
receptor (EGFR), which is combined with conventional chemotherapeutic drugs 
to treat NSCLC patients. Finally, cancer vaccines are a type of immunotherapy 
to enable the immune system to recognize and destroy lung cancer cells [6]. 
Despite some progress, it is important to continue developing novel vaccines 
that boost human immunity to prevent the initiation and progression of lung 
cancer.  
1.2. Cancer vaccines       
1.2.1. Cancer vaccine classification 
A cancer vaccine can either prevent tumor development or treat existing 
malignancy by modulating the immune system [6]. While vaccines designed to 
prevent cancer initiation and progression are classified as preventive cancer 
vaccines, vaccines that treat cancer patients are known as therapeutic cancer 
vaccines.  
1.2.1.1. Preventive cancer vaccines 
Tremendous success has been achieved in developing prophylactic vaccines 
against infectious agents. For certain cancer types, the cause of cancer is viral 
infection, which is relatively simple compared with the complex processes 
involved in the development of other human cancers and well established [6]. 
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While liver cancer has been found to be induced by human hepatitis B virus 
(HBV), cervical cancer can be caused by human papilloma virus (HPV) infection. 
Exploiting the rich experience gained against infectious diseases, researchers 
have developed several preventive cancer vaccines to prevent HBV or HPV 
infection, resulting in protection against the development of HBV- and HPV-
caused cancer. The first preventive cancer vaccine approved by the FDA is an 
anti-HBV vaccine [7]. Later, two preventive vaccines, Gardasil® and Cervarix®, 
gained FDA approval for clinical application for their protection against infection 
of two HPV subtypes (type 16 and 18) that are responsible for 70 percent of 
cervical cancer in the world [8]. 
However, the pathogenesis of most cancer types is very complicated and 
many factors contribute to the initiation and progression of cancer [6]. Unlike 
viruses, which are foreign to the human immune system and recognized as 
“non-self”, these cancer cells more closely resemble their healthy, normal 
counterparts in human body. Thus, tumors bearing “self” antigens are able to 
evade immune surveillance, making it difficult to develop preventive vaccines. 
Therefore, more sophisticated strategies are required to generate effective 
vaccines to prevent cancer that is not associated with infection of a particular 
virus. It is critical to develop a vaccine that exhibits broader antitumor efficacy 
to prevent the outgrowth of various cancers.  
1.2.1.2. Therapeutic cancer vaccines 
Therapeutic cancer vaccines eliminate tumor cells by promoting human 
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immune system against cancer [6]. Distinct from preventive cancer vaccines, 
therapeutic cancer vaccines are designed to target cancer cells directly. 
Therefore, therapeutic cancer vaccines are used to treat patients with 
established cancers. Normally, therapeutic cancer vaccines may be generated 
by patients’ own cells, including tumor cells and dendritic cells, which promote 
robust immune responses against cancer. Sipuleucel-T, a dendritic cell vaccine, 
is the first immunotherapy product approved by the US FDA to treat metastatic, 
castration-resistant prostate cancer in men [9]. This vaccine recognizes 
prostatic acid phosphatase (PAP), an antigen expressed on prostate cancer 
cells, to promote T-cell-mediated immune responses against prostate cancer 
cells. Sipuleucel-T is generated by in vitro activation of antigen-presenting cells 
(APCs) isolated from a patient’s blood by an immunostimulatory cytokine and 
subsequent infusion of activated APCs back into the patient [10]. However, this 
expensive vaccination strategy only improves overall survival of patients with 
advanced prostate cancer by about 4 months. 
Therapeutic cancer vaccines may also be generated from tumor-
associated antigens identified on specific types of cancer cells [6]. Such a 
vaccine is capable of triggering immune responses in any patient bearing the 
antigens. Unfortunately, the majority of vaccine-based therapeutic strategies for 
cancer have been largely unsuccessful [11]. The probability of generating a 
vaccine with a broad spectrum of anti-cancer activities could be greatly 
increased when different tumor-associated antigens presented by various 
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tumors, but not by adult tissues, are accessible to the immune system. This 
vaccination strategy is advantageous over other tumor antigen-based 
treatments, which have shown limited effectiveness in clinical trials, probably 
due to their inherent shortcomings [12]. 
1.2.2. Cancer vaccines in development 
1.2.2.1. Embryonic material-based cancer vaccines 
In most tissues, stem cells are the only type of cells capable of self-renewal, 
whereas other cell types have a much shorter lifespan of days or weeks [13]. 
Emerging research about cancer immunization focuses on studying cancer 
cells and stem cells due to the similarities between them. An earlier study has 
demonstrated that cancer tissue can be viewed as a newborn abnormal organ 
formed by the accumulation of tumor cells [14]. To eliminate the side effects of 
vaccination, cancer vaccines should be developed to avoid influencing somatic 
stem cells.  
So far, many of the known cancer cell surface markers can also be detected 
on adult stem cells [15]. The similarity in cell markers between tumor cells and 
normal stem cells has provided evidence for researchers to envision that 
cancers arise from remnant embryonic cells in human body [16]. Except for the 
same surface markers, cancer cells and embryonic cells also share some 
common properties, including histological morphology, reduced contact 
inhibition, high proliferation rate, tissue invasion ability, anaerobic metabolism, 
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dedifferentiation status, evasion of immune destruction, secretion of angiogenic 
factors, and expression of embryonic genes[17]. 
The history of immunizing animals with fetal tissues to elicit an antitumor 
response dates back a century [18]. It was found that most types of neoplastic 
cells express certain embryonal antigens, a phenotype described as 
'retrogenetic expression' [19]. Subsequent reports indicate that transplantable 
and chemically induced tumors could be prevented by vaccination with 
embryonic materials that induce cancer-specific immunity. The antigens shared 
between tumors and embryos have been identified during the past century [18] 
[20]. Initially, the similarities were thought to be restrained within digestive 
related tumors [21]. Subsequent studies came up with the concept of “oncofetal 
antigens” that are found only at early stages of embryonic and fetal 
development, but are also present in cancerous tissues [22]. The oncofetal 
antigens are present in most types of tumors, and embryonic materials were 
demonstrated to be effective against implantable tumors [23]. This viewpoint 
has been validated using human embryonic material [24] as Klavins et al. 
reported that the rabbit antisera against human embryos recognized human 
tumors, such as lung, colonic and renal cancer. Additional research has also 
provided evidence that embryonic cells induce the production of antibodies 
recognizing both tumors and embryos [25]. These results help to support the 
notion that vaccination with embryonic materials could potentially stimulate the 
immunity against different types of tumors, probably by recognizing the markers 
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shared by cancer cells and embryonic cells.  
1.2.2.2. Whole-cell cancer vaccines 
Early cancer vaccination strategies focused on using irradiated, autologous 
tumor cells, which has the advantage of inducing tumor-specific CD4+ and CD8+ 
T cell responses against multiple tumor-associated antigens (TAAs) [26]. 
However, this vaccination approach has been hampered by the challenge of 
collecting large amounts of patient-specific, contaminant-free malignant cells. 
The efforts to utilize immunostimulatory cytokines as vaccine adjuvants has 
greatly advanced progress in this area of research. For instance, GVAX is a 
vaccine composed of irradiated, syngeneic tumor cells genetically engineered 
to produce the immune stimulatory cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF) [27]. GVAX has displayed antitumor capability by 
promoting specific, robust, and enduring immune responses in preclinical 
studies either as a monotherapy or in combination with other 
immunotherapeutic agents. However, two Phase III trials of GVAX for patients 
with advanced prostate cancer were terminated in 2008 due to a lack of efficacy. 
Five years later, a Phase II clinical trial testing the effectiveness of GVAX 
combined with a PD-1 inhibitor to treat pancreatic cancer ended without much 
success. Although the exact reasons for the lack of success of GVAX in clinical 
trials are unclear, it is conceivable that potent immune evasion mechanisms in 
cancerous tissues contributed to the clinical failure of GVAX. Thus, the 
likelihood of success is highly increased if a whole-cell vaccine is designed to 
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block the escape of tumors from immune surveillance.  
It is now evident that stem-like cells (cancer stem cells; CSCs) and more 
differentiated trophoblast-like cells coexist within cancerous tissues [15]. CSCs 
have been identified in a large number of human malignancies [15]. The 
presence of CSCs is a particular challenge in developing cancer vaccines, 
because they play an important role in cancer immune evasion [28]. If CSCs 
could be targeted in developing cancer vaccines, their antitumor efficacy would 
be greatly enhanced.    
Based on the mechanisms by which CSCs escape from the immune system 
and antigens shared between fetal tissues and CSCs, vaccines containing 
embryonic stem cells (ESCs) have been explored for their effectiveness in 
boosting antitumor immunity. Among them, a unique prophylactic vaccine 
comprised of irradiated, allogeneic murine ESCs and irradiated murine STO 
fibroblasts engineered producing GM-CSF has been generated (ESCs/GM-
CSF vaccine) [29]. This vaccine effectively inhibited the initiation and 
progression of both implantable and carcinogen-induced lung adenocarcinoma 
in mice without generating detectable toxicity and autoimmune responses. 
Importantly, irradiated GM-CSF-expressing fibroblasts alone failed to protect 
against the outgrowth of lung tumors, indicating that the vaccine efficacy is not 
elicited by non-specific immune responses against allogeneic, whole cell 
antigens. The effectiveness of ESCs/GM-CSF vaccine is linked to the 
generation of robust tumor-specific primary and memory CD8+ T effector 
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responses, Th1 cytokine response, decreased tumor-suppressive myeloid-
derived suppressor cells in the spleen and increased ratio of intratumoral CD8+ 
T effector/T regulatory cells (Tregs).   
A more recent study lends credence to the idea that undifferentiated stem 
cells could function as a vaccine against cancer [30]. Kooreman and colleagues 
have utilized irradiated, syngeneic induced pluripotent stem cells (iPSCs) and 
the immunostimulatory adjuvant CpG to generate a stem cell-based vaccine. 
This vaccine is capable of activating the immune system to recognize the 
antigens shared between iPSC and cancer cells to confer antitumor immunity. 
This vaccination strategy not only blocked the outgrowth of implanted primary 
tumors, but also suppressed the recurrence of resected tumors in an adjuvant 
setting in mice. Immunization with the iPSC-based vaccine generated effective 
anti-cancer immune responses by a systemic boost in CD4+ T helper and CD8+ 
cytotoxic T cell responses. This study provides robust evidence for the idea that 
embryonic material can function as a potent cancer vaccine. 
Similarly, immunization with undifferentiated, pluripotent ESCs in the 
absence of any immunostimulatory adjuvant only conferred modest antitumor 
function against implantable colorectal and pulmonary malignancies in mouse 
models of cancer [25, 31]. All of these studies provide robust evidence for the 
idea that ESCs with the help of an immunostimulatory adjuvant can function as 
a potent cancer vaccine against embryonal antigens expressing at early 
embryonic development stages but not in adult tissues. The key to the success 
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of ESC-based cancer vaccines lies in the fact that oncofetal antigens shared by 
both embryos and malignant cells are potentially immunogenic due to their 
absence in the ‘self’ repertoire of humans.  
1.2.2.3. Peptide cancer vaccines  
Recently, tremendous progress has been achieved towards understanding the 
unique tumor-associated antigens (TAAs) existing in various tumors. T cells are 
known to be able to recognize antigen-originated peptide fragments presented 
by major histocompatibility complex (MHC) molecules at the surface of APCs 
and subsequently elicit specific immune responses. Thus, the peptide epitopes 
derived from TAAs have been explored as antitumor therapeutic vaccines [32]. 
Compared with whole-cell vaccines, peptide-based vaccination strategies hold 
several advantages, such as inexpensive production of peptides in large 
quantities at clinical grade, easy administration into cancer patients, and limited 
toxicity. However, tumor cells are able to acquire various genetic and epigenetic 
changes during the “escape” phase of cancer immunoediting process, fostering 
an immunosuppressive tumor microenvironment [33]. This enables malignant 
cells to alter their antigenic profiles, such as loss of the expression of MHC 
molecules or immunogenic TAAs, thereby evading the recognition by the 
immune system. Therefore, a major limitation of peptide-base vaccination is the 
resistance to immune elimination conferred by the escape of cancer cells from 
immune recognition. In this scenario, tumor subpopulations lacking MHC 
molecules or TAAs will be positively selected and propagate as their 
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counterparts expressing MHC molecules or TAAs will be eliminated by T cells. 
A number of peptide-based cancer vaccines have been developed to utilize 
recombinant or synthesized epitopes of immunogenic TAAs, and they are 
designed to stimulate immune responses against one or more TAAs [32]. In the 
clinic, peptide-based cancer vaccines have generally displayed limited toxicity 
with only mild side effects reported. Researchers had high hopes for peptide-
based cancer vaccination strategies in the beginning. Indeed, immunization 
with peptide-based cancer vaccines elicits certain degrees of immune 
responses targeted on tumors, such as production of antitumor cytokines, 
infiltration of CD4+ and CD8+ lymphocytes into malignant tissues, and detection 
of epitope-specific antibodies in the serum. However, the anti-cancer efficacy 
of peptide-based cancer vaccines as standalone therapeutics has been largely 
disappointing during a variety of clinical trials. This failure could be attributed to 
the immunoediting selection of non-immunogenic tumor cells as well as the 
strong immunosuppressive microenvironment promoted by cancer cells. 
Therefore, the current phase of developing peptide-based vaccines is focused 
on overcoming immunoediting by combination with immunotherapeutic 
approaches to reverse immunosuppression and enable tumor-specific immune 
responses. This strategy could potentially unlock the full capability of cancer 
vaccines and likely provide enduring protection against recurrence of 
malignancies. 
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1.2.3. Cancer vaccine adjuvants 
For cancer vaccination, specific vaccine antigens are normally used in 
combination with adjuvants to potentiate and modulate antigen-specific 
immune responses [34]. Without an adjuvant, a cancer vaccine only provides 
modest effects from antigens alone. An adjuvant could enhance the efficacy of 
cancer vaccines through various mechanisms, such as promoting cytokine 
production, increasing the association between the antigens and APCs, 
prolonging antigen presence in the blood, and activating antitumor immune 
cells.  
1.2.3.1. Cytokines  
Cytokines are a broad group of natural peptides (~5–20 kDa) that function as 
important immunomodulating agents. Since cytokines are deeply involved in 
normal immune responses, they hold great promise as potential adjuvants for 
cancer vaccines [35]. 
1.2.3.1.1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
Colony-stimulating factors (CSF) are secreted glycoproteins that were 
discovered by chance in the observation of proliferating granulocytes and 
macrophages in a tissue culture system [36]. CSFs play an important role in 
haematopoietic cell activation, survival, differentiation, and proliferation. 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a subtype of 
CSF produced by macrophages, T cells, mast cells, natural killer (NK) cells, 
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endothelial cells, and fibroblasts [37]. GM-CSF stimulates differentiation, 
proliferation of stem cells, and increases the production of macrophages and 
dendritic cells necessary for activating T cells. Therefore, GM-CSF is an 
essential component of the normal immune cascade.   
As a growth factor, GM-CSF primarily functions as a multifunctional 
haematopoietin to promote production of several blood cell lineages [37]. In the 
case of non-haematopoietic function of GM-CSF, there is still a lot to be 
discovered. As a key part component in a number of signaling cascades to 
activate the immune system, GM-CSF can stimulate different signaling 
pathways in various immune cells to enhance immune responses. For instance, 
human T cells can be activated by GM-CSF-mediated increase in MHC-II 
expression in neutrophils, which is involved in the toll like receptor 4 (TLR4) 
signaling [38]. In monocytes, the expression of toll-like receptor 2 (TLR2) and 
tumor necrosis factor alpha (TNF-α) is stimulated by GM-CSF to initiate host 
innate immune responses [39]. Moreover, GM-CSF promotes differentiation of 
dendritic cells in mouse bone marrow [40]. Specifically, GM-CSF activates 
signal transducer and activator of transcription 5 (STAT5) expression in 
dendritic cells, which in turn upregulates the cytoplasmic cytokine inducible 
SH2domain (CISH) protein and promotes subsequent type 1 dendritic cell 
development [40]. Because of its effect on dendritic cell activation, GM-CSF 
also plays an important role in differentiation of Th1 type cells, as the expression 
of MHC-II molecules and immune response in monocytes and dendritic cells 
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were enhanced when treated with GM-CSF [41].  
The impact of GM-CSF on the immune system makes it critical in different 
types of diseases related to immune response, particularly cancer. For instance, 
GM-CSF has been utilized in a dendritic cell-based vaccine against prostate 
cancer, in which a fusion protein consisting of GM-CSF and the prostate cancer 
antigen PAP activated patient's dendritic cells before they were reinfused into 
the patient to stimulate T cell activation and cancer cell elimination [42]. In 
another study, GM-CSF and antisense transforming growth factor (TGF)-β2 
were co-expressed in isolated tumor cells from a patient to generate a 
autologous cancer vaccine [43]. Similarly, a vaccine against melanoma was 
designed with a plasmid encoding both GM-CSF and the tumor antigen MAGE-
1, which can stimulate an antigen-specific immune response through the 
production of IFN- and IL-6 [44]. Moreover, GM-CSF along with IL-12 has been 
tested in clinical trials as a treatment against lung cancer [45]. 
In many preclinical studies, GM-CSF has been investigated as an adjuvant 
for prophylactic vaccines protecting against infectious diseases and 
malignancies. Due to its modulatory role in immune responses suppressing 
tumor growth, Nemunaitis et al. evaluated a vaccine with autologous tumor cells 
modified to overexpress GM-CSF in patients with early and advanced stage of 
NSCLC [46]. Longer survival was observed in the patients vaccinated with GM-
CSF-expressing tumor cells compared with those immunized with tumor cells 
only. Furthermore, a preclinical study has shown that GM-CSF is essential for 
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anti-cancer efficacy of a prophylactic lung cancer vaccine [29]. Overall, these 
results provide evidence that GM-CSF possesses the potential as an adjuvant 
in prophylactic or therapeutic cancer vaccination.  
GM-CSF has been extensively explored for its anti-cancer function to 
stimulate tumor antigen presentation by recruiting dendritic cells and mediate 
protective immunity by activating CD4+ and CD8+ T cells [47]. It is worthy to 
note that GM-CSF is also capable of stimulating tumor progression under 
certain circumstances. For instance, GM-CSF appears to enhance proliferation 
and invasion of lung cancer cells by increasing productions of gelatinases and 
urokinase plasminogen activator [47]. In mesothelioma patients, GM-CSF 
produced by tumors stimulates tumor progression through promoting 
immunosuppression of granulocytes in tumor microenvironments [48]. 
Therefore, more studies are warranted to elucidate the complexities of GM-CSF 
clinical applications. 
1.2.3.1.2. IL-23  
IL-23 is a heterodimeric cytokine secreted by activated dendritic cells, which is 
composed of the IL-12p40 subunit and IL-23p19 subunit [49]. The main function 
of IL-23 in the immune system is stimulating IFN-γ production from CD4+ T cells. 
Some studies have revealed that IL-23 promotes immunity to target antigens of 
endogenous antitumor immunity [50]. In another research, the immunological 
and antitumor effects of IL-23 on gp100-specific vaccination therapy of human 
melanoma were examined [51]. In this in vivo experiment, systemic IL-23 
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administration alone failed to stimulate effective tumor immunity. However, as 
an adjuvant of gp100 peptide immunization, IL-23 helped suppressing tumor 
growth through vaccination-induced T cell activation [51]. Moreover, tumor-
specific T cell levels increased in spleen but not in tumor tissues. It is also 
demonstrated that IL-23 is a potent vaccine adjuvant enhancing intratumoral T 
cell effector function, rather than increasing intratumoral T cell number for tumor 
suppression. However, IL-23 produced drastic side effects, including the rapid, 
systemic, vaccination-independent depletion of nonspecific CD8+ and CD4+ T 
cells. Another toxicity of IL-23 was weight loss caused by reduced appetite. 
While IL-23 is promising in cancer vaccine adjuvant, further research is required 
to fulfill its potential by eliminaing the side effects.  
1.2.3.2 CpG   
First identified in a bacterial genome, CpG is unmethylated deoxycytidyl (“C”)-
deoxyguanosine (“G”) dinucleotides linked by a phosphodiester (“p”) bond [52]. 
Since CpG motifs have been widely discovered in microbial genomes but rarely 
identified in vertebrate genomes, they are believed to possess pathogen-
associated molecular patterns (PAMPs). It has been found that the pattern 
recognition receptor toll like receptor 9 (TLR9) in human B cells and 
plasmacytoid dendritic cells is able to recognize the CpG PAMPs to elicit the 
innate immune response with the production of Th1 and proinflammatory 
cytokines. Due to the critical role of plasmacytoid dendritic cells in triggering 
immune responses required for tumor elimination, it is appealing to utilize CpG-
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based adjuvants for cancer vaccines. 
CpG-based cancer vaccine adjuvants are normally designed as synthetic 
short single-stranded DNA oligodeoxynucleotide molecules containing 
unmethylated CpG motifs [52]. As adjuvants for cancer vaccines, CpG 
oligonucleotides have been shown to enhance activities of professional APCs 
and generate tumor-specific immune responses in pre-clinical studies. In recent 
research focusing on an iPSC-based cancer vaccine, CpG oligonucleotides 
were employed as adjuvants to help suppressing tumor growth in mice [30]. In 
a prophylactic setting, immunization of CpG and irradiated iPSC inhibited breast 
cancer, mesothelioma, and melanoma in syngeneic mouse models. 
Furthermore, this vaccine blocked the recurrence of melanoma at the original 
resection sites. To further explore the immunity induced by this vaccine, 
Kooreman and colleagues performed adoptive transfer of iPSC/CpG-primed T 
cells to immunocompetent mice bearing breast cancer and tumor-experienced 
lymphocytes to iPSC-inoculated non-obese diabetic severe combined 
immunodeficiency (NOD-SCID) mice. In both cases, tumor growth was reduced, 
indicating that CpG promotes tumor-specific immunity against shared epitopes 
between iPSCs and cancer cells.   
1.2.3.3. Others  
Beyond glycoproteins, cytokines, and CpG oligodeoxynucleotides, other 
adjuvants have been explored [53, 54]. For instance, mineral salts have also 
been adopted in vaccine formulations, including insoluble aluminum salts and 
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calcium phosphate, which can induce early and long-lasting immunity 
responses. In addition, bacteria-derived adjuvants, saponin and oil adjuvants 
have been proved to display different biological and pharmacological activities 
in cancer immunity induced from vaccination. 
1.3. Exosomes in cancer therapy 
1.3.1. Biogenesis of exosomes  
Extracellular vesicles (EVs) are a type of membrane capsule released from 
parental cells and range in size from 20 nm to 200 nm in diameter [55]. EVs 
were firstly found in 1946 as platelet-derived particles by Chargaff and West 
[56]. After a series of studies, EVs were discovered to perform numerous 
essential functions in intercellular communication [57-59]. In multicellular 
organisms, they can be found in nearly all tissues and body fluids [60]. EVs 
regulate physiological and pathological functions by transferring their cargo, 
such as proteins and nucleic acids, between cells. Among different subtypes of 
EVs, exosomes are small membrane vesicles released from various cell types 
into the extracellular space upon fusion of intermediate endocytic 
compartments, multivesicular bodies (MVBs), with the plasma membrane [61]. 
1.3.2. Composition of exosomes 
As a subtype of EVs, exosomes have spherical or cup-shaped construction and 
their size is normally in the range of 30–100 nm in diameter. The existence and 
biological function of exosomes have been investigated since the mid-20th 
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century [55]. It is now known that exosomes inherit biological functions from 
their own parental cells, as they contain biological materials acquired from the 
cytosol, including proteins, RNA, double-stranded DNA, and metabolites [62]. 
These exosomal molecules are either located inside exosomes or associated 
with their membrane. Exosomes normally contain general as well as cell type-
specific proteins with various bioactivities. The protein profiles of exosomes are 
similar to those identified in the endocytic pathway, plasma membrane, or 
cytosol [61]. A select set of functional coding (mRNAs) or non-coding 
(microRNAs) nucleic acids are also enriched in exosomes. It is hypothesized 
that the presence of double-stranded DNA in exosomes from certain types of 
cells, particularly cancer cells, could serve as a biomarker [62]. On a similar 
note, the metabolomic profiles of exosomes circulating in blood and other bio-
fluids also display diagnostic potential in detecting various diseases, including 
cancer [61]. The composition of exosomes could be examined by various 
biological techniques, such as western blotting, flow cytometry, and 
spectrometry.  
1.3.3. Functions of exosomes in tumorigenesis 
Tumors are composed of a heterogeneous population of malignant cells along 
with resident and infiltrating non-transformed cells [63]. Dynamic interactions 
between cancer cells and non-malignant cells are critically involved in every 
stage of carcinogenesis, as well as responses to cancer therapies. As major 
conveyors of intercellular communication, exosomes play an important role in 
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the crosstalk between cancer cells and other types of cells in malignant tissues, 
particularly immune cells infiltrating into tumors [64].  
Emerging evidence indicates that tumor-derived exosomes profoundly 
influence the functions of intratumoral immune cells. In some cases, exosomes 
derived from tumors enhance immunity against cancer. For instance, exosomes 
derived from melanoma tumors could be recognized by T cells through the 
endogenous tumor antigens present on exosomes [65]. Furthermore, exosomal 
tumor antigens could be transferred to dendritic cells to elicit robust CD8+ T cell-
dependent antitumor immune response in syngeneic and allogeneic mouse 
tumor models [66]. On the other hand, tumor-derived exosomes are also 
capable of boosting pro-tumor immune signaling [67]. One example is that 
exosomes of a variety of tumors promote tumor-associated macrophages 
known to stimulate cancer progression and metastasis.  
Immunocyte-derived exosomes also play a multifaceted role in regulating 
tumor immunity, rather than just inhibiting or promoting malignancies [68]. 
Exosomes released from antitumorigenic immune cells often block 
carcinogenesis [68]. Like their parental cells, exosomes originating from 
dendritic cells possess high levels of transmembrane TNF, Fas ligand (FasL), 
and TNF-related apoptosis-inducing ligand (TRAIL) that induce apoptotic 
signaling in a variety of tumors [69]. Furthermore, NK cells are also activated 
by exosomes of dendritic cells to produce antitumor cytokines [69]. On a similar 
note, exosomes derived from NK cells are enriched in FasL and perforin, which 
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eliminate human melanoma cells but not unmalignant cells [70]. In contrast, 
exosomes derived from pro-tumor immune cells, such as tumor-associated 
macrophages, normally promote tumor evasion from immune surveillance [68]. 
1.3.4. Exosome-based cancer vaccines  
Since tumor-associated antigens or factors stimulating tumor-specific immune 
responses are encapsulated in the exosomes from either malignant cells or 
certain types of immunocytes, numerous investigations have explored 
exosomes as an anti-cancer vaccination strategy [68]. The first study about the 
role of exosomes in immunotherapy was conducted in the 1990s, in which the 
exosomes isolated from B cells were found to stimulate an antigen-specific T 
cell response [71]. Subsequent in-depth characterization of exosomes at the 
molecular level and standardized exosome isolation and storage protocols 
have greatly advanced pre-clinical and clinical studies of exosome-based 
cancer vaccines, which display significant advantages over their cell-based 
counterparts. Among exosomes derived from different sources, those 
originated from dendritic cells and tumor cells have drawn notable interest due 
to their particular biological functions to promote tumor-specific immune 
response. 
Dendritic cell-derived exosomes (Dexosomes) inherit the ability to initiate 
an antigen-specific immune response from their parental cells [72]. These 
exosomes are enriched in peptide-MHC-I and peptide-MHC-II complexes that 
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are 10–100 times more abundant than those in dendritic cells. In addition, 
Dexosomes harbor co-stimulatory factors (e.g. CD40, CD80, and CD86) as well 
as other molecules involved in immune responses. Pre-clinical research has 
demonstrated that Dexosomes elicit robust antitumor immune responses that 
activate cytotoxic T cells and NK cells in vitro and in vivo [72], which paved the 
way for human clinical trials of Dexosomes as a cell-free cancer vaccine. Two 
phase I clinical trials and one phase II clinical trial of Dexosomes have been 
carried out in patients with advanced malignancies. In the first phase I clinical 
trial with melanoma patients, exosomes from autologous dendritic cells pulsed 
with melanoma-associated antigen (MAGE) peptides were utilized to immunize 
stage III/IV melanoma patients. The safety of exosome inoculation was 
examined and tumor-specific T cell responses was determined [73]. The 
second phase I clinical trial tested a vaccine composed of Dexosomes loaded 
with the MAGE tumor antigens in patients with advanced NSCLC [74]. This 
Dexosome-based vaccine evoked immune responses in some patients and 
exhibited limited toxicity, but its antitumor efficacy appeared to be modest. 
Following up the phase I clinical trials, a second generation of Dexosome-based 
cancer vaccine was developed [75]. The new vaccine was composed of 
exosomes derived from TLR4L- or interferon (IFN)--maturated dendritic cells 
that elicited more robust T cell stimulation compared with their counterparts 
from immature dendritic cells. This phase II trial of patients with advanced 
NSCLC improved upon the limited T cell-mediated immune responses 
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observed in the phase I studies and enhanced the capacity of Dexosomes to 
boost NK cell-mediated antitumor immunity. Overall, these clinical trials have 
demonstrated the feasibility and safety of Dexosome-based vaccine, as well as 
the ability of Dexosomes to evoke T cell- and NK cell-based immune responses 
in patients with advance malignancies.  
Tumor-derived exosomes (Texosomes) have been considered as a specific 
stimulus for antitumor immunity, since they are enriched in MHC-I molecules, 
antigens, and heat shock proteins (HSPs) that could increase immune 
responses, particularly cytotoxic T cell activation [76], [77]. More importantly, 
Texosomes evoke immune responses against tumors more effectively than 
either irradiated live cancer cells or their lysates [78]. Since Texosomes are 
capable of transferring a selection of tumor antigens to dendritic cells, they have 
been explored as the carriers for tumor antigens in cancer immunotherapy [68]. 
Although Texosomes could potentially serve as a cell-free cancer vaccine, in 
vitro expansion of purified autologous malignant cells from patients is 
challenging in clinical settings. It has been shown that large amount of 
Texosomes are present in the biological fluids of patients, such as ascitic fluid 
[78]. Due to their high abundance, Texosomes isolated from the ascitic fluid of 
patients with advanced colorectal carcinoma (CRC) were investigated for their 
potential as a cancer vaccine [79]. Like Texosomes from other sources, ascites-
derived Texosomes were enriched in MHC-I and MHC-II molecules, HSPs (e.g. 
HSC70, HSP70, and HSP90), co-stimulatory molecules, intercellular cell-
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adhesion molecule-1 (ICAM-1), and the classical carcinoembryonic antigen 
(CEA) of CRC. A phase I clinical trial was conducted with ascites-derived 
Texosomes in the absence of presence of immunostimulatory factor GM-CSF 
[79]. This vaccination strategy was safe and well-tolerated in CRC patients. 
Importantly, ascites-derived Texosomes along with GM-CSF, but not ascites-
derived Texosomes alone, induced beneficial CEA-specific antitumor cytotoxic 
T lymphocyte (CTL) response, demonstrating its potential as a cancer vaccine 
candidate. 
However, it is noteworthy that the Texosomes from some tumor cells 
promote tumor growth and angiogenesis [80], as they contain a large part of a 
protein repertoire to suppress immune responses or exacerbate tumor cell 
proliferation by different molecules. Moreover, Tumor-derived exosomes can 
induce resistance to the immune response by decreasing antitumor T cells [78, 
81]. The utilization of Texosomes as tumor vaccines depends on the types of 
malignancies and the immunogenicity of their antigens. Thus, further research 
is needed to unlock the immunogenic potential of Texosomes. 
1.4. Hypothesis and significance of the project 
Numerous studies have focused on prophylactic vaccines against diseases, 
since they can decrease or even eradicate a disease around the world. For 
infectious disease control, vaccination is effective, because the pathogen can 
be recognized by the immune system after the vaccine provides actively 
acquired immunity. However, tumors have not been conquered by antitumor 
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vaccination, because tumors cells are recognized as “self” by the immune 
system. As a result of tumor cell escaping from immune surveillance, tumors 
continue developing and metastasizing. To date, a number of vaccination 
strategies stimulating tumor-specific immune responses have been explored as 
immunotherapy against cancer, among which tumor cell lysates and tumor 
antigens have been extensively studied [82]. However, the therapeutic effects 
of most antitumor vaccines are not significant in clinical trials. The only FDA-
approved cancer treatment vaccine is Sipuleucel-T that treats metastatic 
prostate cancer patients with limited improvement of survival [83].  
ESCs display the characteristics of self-renewing and they are multipotent 
cells. A vaccine comprised of allogeneic murine ESCs and murine fibroblasts 
expressing the immunostimulatory factor GM-CSF successfully blocked the 
outgrowth of lung tumors in different mouse models [29]. However, an intact 
ESC-based cancer vaccine raises ethical concerns and the potential risks of 
inducing teratomas and autoimmunity. Exosomes isolated from ESCs inherit 
some functions of ESCs as they possess the antigens of ESCs. Because of the 
similarity of antigens between ESCs and tumor cells, it is possible that ESC-
derived exosomes could serve as a cancer vaccine to suppress tumor growth. 
Therefore, we hypothesized that the exosomes derived from ESCs would 
function as a novel cell-free vaccine to effectively prevent lung tumor 
development in mice. The success of this study will have important implications 
for lung cancer prevention and could potentially lead to clinical trials of a similar 
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human vaccine.   
CONCLUSION 
Embryonic materials have a long history of being studied as a preventive 
strategy against cancer in animal experiments due to their antigenic similarities 
to tumor cells. However, the prophylactic function of ESCs against cancer is still 
under investigation. Given that exosomes hold great promise as diagnostic 
biomarkers and therapeutic vehicles, using ESC-derived exosomes as a cancer 
vaccine possesses high potential to prevent lung cancer development. The 
experiments proposed in this study will address significant unanswered 
questions pertaining to the potential of ESC-derived exosomes as an immune-
prophylactic agent for lung cancer.    
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CHAPTER II 
EXOSOMES DERIVED FROM MURINE EMBRYONIC STEM CELLS OVER-
EXPRESSING GM-CSF PREVENT TRANSPLANTED LUNG TUMOR 
DEVELOPMENT 
INTRODUCTION  
An early hypothesis of tumorigenesis suggests that mutations in 
undifferentiated progenitor cells give rise to malignant cells that are capable of 
both self-renewal and differentiation. Interestingly, this theory essentially 
predicts the discovery of cancer-initiating cells (CICs) that came over 100 years 
later. In the mid-1960s, tumor cells and embryonic stem cells were shown to 
possess common gene products such as the oncofetal antigens [84]. During 
the next decade, a large number of studies confirmed these findings and 
revealed that embryonic antigens are re-expressed in malignant cells from a 
number of different tissues and that vaccination of animals with fetal material 
can prevent the outgrowth of tumors [18]. It now appears that most, if not all, 
types of neoplastic cells express certain embryonal antigens, termed as 
“retrogenetic expression” [19]. Many of these embryonic gene products (also 
called carcinoembryonic antigens) are not expressed in the adults and thus, are
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not included in the repertoire of ‘self’ during the process of thymic selection that 
occurs near the end of gestation. Such ‘non-self’ embryonic antigens are 
immunogenic and can prime the immune cells to mount an anti-tumor response 
[85]. Exploiting such embryonic antigen immunogenicity, we have designed a 
unique stem cell-based vaccine that stimulates the immune system to 
recognize shared oncofetal antigens and confers protection against tumors.  
In our initial attempts to produce a prophylactic vaccine, we successfully 
combined irradiated allogeneic murine embryonic stem cells (ESCs) with 
murine STO fibroblasts expressing GM-CSF (STO-GM) as an immune 
stimulant (ES cell vaccine) [29]. We discovered that ES cell vaccination was 
70–100% effective in preventing both implanted and carcinogen induced lung 
adenocarcinomas.[29] Vaccinated mice remained tumor-free over a 90-day 
observation period. A very recent study by Kooreman et al. [30] supports our 
earlier results albeit with a different form of pluripotent stem cells (induced 
pluripotent stem cells; iPSCs) and a different adjuvant (CpG) and lends further 
credence to the theory that embryonic material can be an effective prophylactic 
vaccine against “other” non-mutated neo-antigens, i.e., tumor antigens derived 
from proteins that are only expressed during embryonic development and not 
in adult tissues.  
Although the ES cell vaccine holds promise for inducing anti-lung cancer 
immune responses, such an approach has two obvious problems in terms of 
application to humans: (i) The use of whole ESCs—although irradiated—raises 
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the risk of generating embryomas/teratomas. (ii) Using murine fibroblasts to 
generate GM-CSF is needlessly complicated. To overcome these challenges, 
we have attempted to develop an alternative cell-free prophylactic vaccine to 
avoid the need for the administration of intact ESCs.  
Exosomes are cell-derived nanovesicles [86] (30–100nm) that have 
recently gained renewed interest as they possess immense potential for cancer 
therapy [87]. Within the cells, invagination and budding from the limiting 
membrane of late endosomes, results in formation of vesicles that contain 
cytosol and the extracellular domain of transferrin receptors at their surface. 
These internal vesicles (called exosomes) are then secreted into extracellular 
environment following the fusion of multivesicular endosomes with the 
plasma membrane [88]. In vitro and in vivo studies suggest that exosomes can 
bind to target-cell membranes, or can fuse with target cells to facilitate the 
exchange of membrane proteins and cytosol between two cell types [89]. 
Importantly, exosomes are also capable of transferring nucleic acids, such as 
mRNA and microRNA, which represent a new paradigm of genetic exchange 
between cells [89, 90]. Recent studies indicate that exosomes can operate as 
potential immunotherapeutic agents, with promising results in pre-clinical 
studies of cancer immunotherapy [87]. Exosomes have several advantages 
over cell-based therapies, including high bio-availability, bio-stability, and lower 
costs [91, 92]. Since exosomes can deliver large amounts of cargo directly to 
target cells, this property can be exploited to include therapeutics as well as 
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immunostimulatory adjuvants in engineered exosomes [93]. 
In this study, we first generated murine ESCs engineered to produce GM-
CSF in amounts similar to those produced by STO fibroblasts in our earlier 
study. Then we purified ESC-derived exosomes (ES-exo), thereby producing a 
self-contained, relatively stable exosome-based vaccine. Here we show that, 
prophylactic vaccination of mice with ESC-exosomes expressing GM-CSF (ES-
exo/GM-CSF) is very effective in preventing implantable lung tumors with no 
detectable toxicity. Importantly, anti-tumor efficacy of the ES-exo/GM-CSF 
vaccine is associated with robust CD8+ T effector responses and infiltration of 
CD8+ T cells into the tumor, leading to increased intratumoral CD8+ T effector/T 
regulatory (Tregs) cell ratio in the tumors. Collectively, our findings provide a 
strong rationale for further developing this novel cell-free exosome-based 
vaccination strategy for the prevention of cancer.   
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MATERIALS AND METHODS 
1. Cell culturing 
Murine embryonic stem cell line ES-D3 was purchased from ATCC (CRL-11632; 
Manassas, VA). To remove exosomes, fetal bovine serum (FBS; SCRR-30-
2020; ATCC) was centrifuged at 100,000 × g for 16 hours at 4°C by a 45Ti rotor 
in an ultracentrifuge (OptimaTm L-100XP, Beckman Coulter; Brea, CA). After 
centrifugation, serum supernatant was used as exosome-free FBS to culture 
ES-D3 cells for exosome preparation. ES-D3 cells were grown in KnockOut™ 
Dulbecco’s Modified Eagle’s Medium (10-829-018; Thermo Fisher; Waltham, 
MA) supplemented with 15% exosome-free FBS, 50 U/ml penicillin (sc45000-
652; Mediatech; Manassas, VA), 50 μg/ml streptomycin (sc45000-652; 
Mediatech), 0.1 mM non-essential amino acids (SH3023801; Thermo Fisher), 
2 mM L-glutamine (L0131-0100; VWR; Radnor, PA), 0.1 mM β-
mercaptoethanol (21985023; Thermo Fisher) and 100 units/ml leukemia 
inhibitory factor (LIF; ESG1106; Thermo Fisher). ES-D3 cells were cultured in 
15-cm tissue culture dishes pre-coated with 0.1% gelatin (ES006B; Thermo 
Fisher) for 30 minutes without feeder layer cells as described before[94]. Murine 
Lewis lung carcinoma (LLC) cell line was obtained from ATCC (CRL-1642). 
Murine mammary carcinoma cell line 4T1 was also acquired from ATCC (CRL-
2539). LLC and 4T1 cells were cultured in medium containing Dulbecco's 
modified eagle's medium (DMEM; SH30243.01; Mediatech), 10% FBS (900-
108; Gemini; Broderick, CA),100 units/ml penicillin (Mediatech) and 100 µg/ml 
streptomycin (Mediatech). ES-D3 cells, LLC cells and 4T1 cells were cultured 
in a 5% CO2 humidified incubator at 37oC and were cultured no longer than 6–
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8 weeks before a new vial of cryopreserved cells were thawed. All of our 
cryopreserved stocks were prepared at passage two after receipt from ATCC 
and were authenticated by ATCC cell bank using the Short Tandem Repeat 
(STR) profiling. 
2. Plasmids 
To generate the plasmid expressing murine GM-CSF cDNA in ES-D3 cells, the 
transfection plasmid pEF1α-FD3ER-IRES-hrGFP was acquired from Addgene 
(37270; Cambridge, MA). In this plasmid, human polypeptide chain elongation 
factor 1α (EF1 α) promoter drives the target cDNA expression along with the 
marker protein humanized Renilla reniformis GFP (hrGFP) [95, 96]. pEF1α-
FD3ER-IRES-hrGFP was first digested with EcoRI to produce the vector 
backbone. While self-ligation of the vector backbone produced the empty 
expression vector pEF1α-IRES-hrGFP, inserting murine GM-CSF cDNA into 
the vector backbone generated pEF1α-mGM-CSF-IRES-hrGFP. All of the 
plasmids were sequenced to confirm their identities. 
3. Exogenous expression of GM-CSF 
ES-D3 cells were transfected with pEF1α-mGM-CSF-IRES-hrGFP or its control 
counterpart pEF1α-IRES-hrGFP along with the plasmid pBabe-Neo (1767; 
Addgene). pBabe-Neo was co-transfected into ES-D3 cells to facilitate 
selection of stably transfected cells.  Briefly, 1.4 x 106 ES-D3 cells were 
cultured in a gelatin-coated 10-cm tissue culture dish with 10 ml medium for 24 
hours, and two dishes of ES-D3 cells were prepared for transfection. Two 
plasmid mixtures were transfected into ES-D3 cells: #1: pEF1α-IRES-hrGFP 
vector and pBabe-Neo; #2: pEF1α-mGM-CSF-IRES-hrGFP and pBabe-Neo. 
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Transfection was carried out using Lipofectamine 2000® transfection 
reagent (11668019; Thermo Fisher) following the manufacturer’s protocol. 
Twenty-four hours after transfection, transfected cells were split into two 10-cm 
dishes and cultured with neomycin (0.5 mg/ml) to eliminate untransfected cells. 
The transfected cells were continuously cultured in the medium containing 0.5 
mg/ml neomycin for 2 weeks to generate bulk population of stably transfected 
ES-D3 cells.  
GFP-positive ES-D3 cells were acquired by flow cytometry sorting (MoFlo; 
Beckman Coulter). A single GFP-positive ES-D3 cell was plated into one well 
of a gelatin-coated 96-well tissue culture plate containing 1 × 103 parental ES-
D3 cells in neomycin-free medium. Co-culturing transfected ES-D3 cells with 
their untransfected parental counterparts ensures that stably transfected single 
ES-D3 cells survive and proliferate as a single clone. Forty-eight hours later, 
neomycin was added to 96-well plates with the final concentration of 0.5 mg/ml 
to eliminate untransfected parental ES-D3 cells. Once GFP-positive ES-D3 
single clones in 96-well tissue grew confluence, they were transferred to 
gelatin-coated 6-cm tissue culture dishes. Clonal ES-D3 cell lines were 
evaluated for their GFP fluorescence intensity by flow cytometry (FACScalibur; 
Beckon Dickinson; Franklin Lakes, NJ). ES-D3 clones expressing either GM-
CSF or the empty vector with high levels of green fluorescence were identified. 
4. Evaluation of pluripotency  
The pluripotency of ES-D3 cells was evaluated using a StemflowTM Human and 
Mouse Pluripotent Stem Cell Analysis Kit (BDB560477; Beckon Dickinson) 
following manufacturer’s protocol. The expression of different pluripotency 
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markers, including SSEA-1, Oct-3/4 and SSEA-4, was measured using flow 
cytometry (FACScalibur; Beckon Dickinson). 
5. Isolation of exosomes 
ES-D3 cells (10 x 106/plate) were plated in 15-cm tissue culture plates 
precoated with 0.1% gelatin with 15 ml exosome-free medium per plate. After 
culturing for 72 hours, medium was collected and stored at 4oC up to 1 week 
without compromising exosome integrity. The collected medium was 
centrifuged at 5,000 × g for 60 minutes at 4°C in a JA-10 rotor using an Avanti® 
J-26XPI centrifuge (Beckman Coulter). After centrifugation, the supernatant 
was collected and transferred into polycarbonate bottles (355622; Beckman 
Coulter) for subsequent ultracentrifugation. The ultracentrifugation was carried 
out at 100,000 × g for 90 minutes at 4°C using a 45Ti rotor with an 
ultracentrifuge (OptimaTm L-100XP, Beckman Coulter). After 
ultracentrifugation, the supernatant was removed without disturbing the 
exosomal pellets. The tight pellets at the bottom of the centrifuge tubes were 
gently washed twice with 1 ml of 1 x PBS to remove any traces of medium. 
Then pellets were resuspended in 1 x PBS, and exosome preparations were 
quantitated by their protein concentrations using BCA (bicinchoninic acid) 
assay (23223; Thermo Fisher). Generally, exosomes containing 4 μg protein 
can be acquired from 1 ml of ES-D3 culturing medium. The exosomal 
preparations were resuspended at a concentration of 5 μg/μl in 1 x PBS and 
stored at -80oC. 
6. Transmission electron microscopy (TEM) 
To fix the exosomes, samples (3–5 μg/μl) were incubated with 2% EM grade 
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paraformaldehyde (15710; Electron Microscopy Sciences; Hatfield, PA) at room 
temperature for 2 hours. Then fixed exosomes (10 μl) were loaded on Cu grids 
with carbon support film (FF200-Cu; Electron Microscopy Sciences). To stain 
the exosomal samples, UranyLess staining solution (22409; Electron 
Microscopy Sciences) was dropped on the Cu grids with exosomes for 1 minute 
at room temperature as suggested by the manufacturer. After being drained 
with a filter paper, the grids were dried overnight at room temperature for TEM 
image acquisition. A transmission electron microscope (HT7700; Hitachi; Santa 
Clara, CA) was used to acquire TEM images. 
7. Evaluating exosomes by western blot analysis  
Exosomes were resuspended in 1 x SDS-PAGE at a concentration of 1.2 mg/ml. 
Exosome lysates (10 μl) were loaded into each well in a 4–20% Bis-Tris gel 
(M42015; GenScript; Piscataway, NJ) and transferred onto PVDF membrane 
(IPVH00010; EMD Millipore; Burlington, MA). The membrane was incubated 
with appropriate primary and secondary antibodies in blotting buffer (1 x PBS 
with 0.2% Tween-20) supplemented with 10% (w/v) non-fat dry milk 
(NC9022655; Thermo Fisher). 
Proteins were detected using an enhanced chemiluminescence detection 
system (32106, Thermo Fisher). Antibodies (Abs) for western blot were: anti- 
Alix mAb (clone AC-15, sc-53540); anti-Annexin V mAb (clone H-3, sc-74438); 
anti-CD81 mAb (clone B-11, sc-166029); anti-Flotillin-1 (clone C-2; sc-74566); 
anti-CD86 mAb (clone D-6, sc- 28347), anti-cytochrome c mAb (clone A-8, sc-
13156) from Santa Cruz Biotechnology (Dallas, TX), anti-calnexin pAb (ADI-
SPA-860); anti-protein disulfide isomerase (PDI) pAb (ADI-SPA-890) from Enzo 
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(Farmingdale, NY), anti-GAPDH pAb (600-401-A33S) from Rockland (Limerick, 
PA), anti-Oxphos COX IV-subunit IV mAb (clone 20E8C12; A21348); 
peroxidase-conjugated goat anti-rabbit IgG (31460); peroxidase-conjugated 
goat anti-mouse IgG (31430) from Thermo Fisher.  
8. ELISA measurement of GM-CSF  
To determine GM-CSF protein concentration, a murine GM-CSF ELISA kit 
(88733422; Thermo Fisher) was used following the manufacturer’s protocol. 
After treated in 100 µl of 1 x PBS with 0.05% Tween-20 at room temperature 
for 30 minutes, ESD3 cell culturing medium was added to an ELISA plate 
coated with capture antibody at 4oC overnight and washed with 1 x PBS + 0.05% 
Tween-20 buffer. Following incubation with detection antibody and avidin-HRP, 
the absorbance at 450 nM was determined using a microplate reader 
(PowerWave XS; BioTek; Winooski, VT). To test the GM-CSF location in 
exosome, GM-CSF protein levels in exosomes were determined using the 
same ELISA protocol but with slight modifications. Briefly, exosomes (0.6 µg) 
were pre-treated in 100 µl of PBS with or without 0.05% Tween-20 at room 
temperature for 30 min. Next, samples were added to an ELISA plate coated 
with capture antibody and washed with either PBS alone or PBS + 0.05% 
Tween-20 buffer. Following incubation with detection antibody and avidin-HRP, 
the absorbance at 450 nM was determined using a microplate reader 
(PowerWave XS; BioTek). 
9. Mice 
Wild-type male C57BL/6 mice and female Balb/c mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). Mice were housed at the University of 
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Louisville Research Resources Facilities (RRF), which has the American 
Association for the Accreditation of Laboratory Animal Care (AAALAC) 
Accreditation and the Office for Protection from Research Risks (OPRR) IACUC 
Assurance. The facility also strictly follows the "Guide for the Care and Use of 
Laboratory Animals" (Institute of Laboratory Animal Resources, National 
Research Council, National Academy Press, 1996). The experiments involving 
mice were approved by University of Louisville IACUC (protocol number: 
18301).  
10. Vaccination and implanted tumor challenge  
Male C57BL/6 mice and female Balb/c mice (6-8 weeks of age, 8 mice/group) 
were immunized twice (days 0 and 7) with vehicle only (1 x PBS, 100 µl/mouse), 
225 µg exosomes isolated from ES-D3 cells expressing the empty vector (ES-
exo) or 225 µg exosomes isolated from ES-D3 cells stably expressing GM-CSF 
(ES-exo/GM-CSF). Mice were injected with 1 x PBS or exosomes by 
subcutaneously (s.c.) in the right flank. On day 14, following vaccination, mice 
were challenged with s.c. inoculation of LLC (0.1 ᵡ 106) or 4T1 (0.1 ᵡ 106) in the 
left flank. Tumor growth was monitored by measuring tumor width (W) and 
length (L) in mm using calipers every other day and tumor volumes (V) in mm3 
were calculated by the following formula: V = (W * W * L) / 2. 
11. Evaluation of Fertility 
Female C57BL/6 mice (8 weeks of age, 4 mice/group) were immunized twice 
(days 0 and 7) with vehicle control (1 x PBS, 100 µl/mouse) or 225 µg exosomes 
containing GM-CSF (ES-exo/GM-CSF). The mice were subjected to s.c. 
inoculation of vehicle control or exosomes in the right flank. Following two 
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weekly vaccinations, each of the female mice from control or vaccination group 
was bred with one male C57BL/6 mouse (10 weeks of age). The litter size and 
gender ratio were evaluated after newly born mice reached 4 weeks of age.   
12. Evaluation of toxicological effects  
Female C57BL/6 mice (8 weeks of age, 4 mice/group) were subjected to two 
weekly vaccinations with vehicle only (1 x PBS, 100 µl/mouse), 225 µg control 
exosomes (ES-exo) or 225 µg exosomes containing GM-CSF (ES-exo/GM-
CSF). One week after completing the second vaccination, whole blood was 
drawn from mice by cardiac puncture immediately following CO2 asphyxiation. 
To examine liver and kidney function, whole blood was transferred to serum 
separator tubes (365967; Beckon Dickinson). One hour post-collection, 
samples were centrifuged for 10 minutes at 10,000 × g, and serum was 
collected from each sample and analyzed by the Research Resource Center 
(RRC) facility at the University of Louisville for non-steroidal anti-inflammatory 
drug (NSAID) toxicological analysis. While the liver function was evaluated by 
measuring alanine transaminase (ALT) and alkaline phosphatase (ALP) levels, 
kidney damage was assessed by levels of creatinine and blood urea nitrogen 
(BUN). Simultaneously, whole blood was collected in EDTA-coated tubes 
(365974; Beckon Dickinson) and analyzed by the RRC facility for complete 
blood count (CBC) analysis. 
13. Flow cytometric analysis.  
Single cell suspensions from spleen were stained with relevant antibodies for 
30 minutes after blocking with anti-CD16/CD32 antibody for 15 minutes at 4 °C. 
After washing, cell surface and intracellularly stained cells were analyzed on a 
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FACSCalibur (Becton Dickinson) and results were analyzed with FlowJo 
software (TreeStar, Inc., Ashland, OR). Antibodies used for evaluating 
splenocytes were: anti-CD3 mAb (clone 17A2, 100222); anti-CD4 mAb (clone 
GK1.5; 100406); anti-CD8 mAb (clone 53-6.7; 100712); anti-CD11b mAb (clone 
M1/70; 101228); anti-Ly6C mAb (clone HK1.4; 128006); anti-Ly6G mAb (clone 
1A8; 127608); anti-CD16/CD32 mAb (clone 2.4G2; 101320) from Biolegend 
(San Diego; CA), anti-CD44 mAb (clone IM7; 17-0441-82); anti-CD25 mAb 
(clone PC61.5; 45-0251-82) from (Thermo Fisher), anti-CD62L mAb (clone 
MEL-14; 553152; BD Biosciences; San Jose, CA). 
14. Intracellular cytokine staining  
Spleens were isolated from mice in different treatment groups 10 days after the 
second vaccination. Splenocytes were stimulated with LLC lysate (50 mg/ml) 
or 4T1 lysate (50 mg/ml) for 4 days. For TNF- and IFN- production, effector 
cells were harvested and restimulated for 6 hours with respective tumor cell 
lysate in the presence of Golgiplug (555029; BD Biosciences) at a 
concentration of 1 μl/ml of culture medium. After restimulation, cells were 
harvested and Fc receptors were blocked using anti-CD16/CD32 antibody. 
Then, cells were stained for surface expression of CD8 and intracellular 
expression of cytokines using Cytofix/Cytoperm kit (555029; BD biosciences) 
according to the manufacturer’s instructions and analyzed by flow cytometry. 
15. Analysis of tumor-infiltrating T cells  
Vaccinated and control mice bearing LLC tumors were euthanized 18–21 days 
after tumor challenge. Solid tumors were dissected, chopped into small pieces 
using surgical scissors, and enzymatically dissociated in HBSS containing 400 
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U/ml collagenase type IV (C9891, Sigma-Aldrich), 0.025 mg/ml hyaluronidase 
(H6254, Sigma-Aldrich), 0.01 mg/ml DNase I (D5025, Sigma-Aldrich) for 2 
hours at 37 °C with occasional shaking. The resultant cells were washed and 
passed through a Ficoll gradient (17144002; GE Healthcare; Chicago, IL) to 
eliminate dead cells. Anti-CD45 antibody was used to selectively exclude 
CD45− tumor cells from analysis. Tumor infiltrating lymphocytes (TILs) were 
then analyzed by flow cytometry for the expression of CD4, CD8, and CD25 
markers. Tregs (Foxp3+) were analyzed using the anti-mouse Foxp3 staining kit 
(00-5523-00; eBioscience). The same number of cells (based on side-scatter 
and forward-scatter analyses) was acquired in all samples. For intracellular 
IFN- and TNF- analysis, TILs were stimulated with LLC lysates (50 mg/ml) 
for 24 hours and restimulated with LLC lysates for 6 hours in the presence of 
Brefeldin A. After restimulation, cells were harvested, treated with Fc block, and 
stained for surface expression of CD8 and intracellular expression of cytokines 
using Cytofix/Cytoperm kit according to the manufacturer’s instructions 
(555029; BD Biosciences) and analyzed by flow cytometry. 
16. Statistical analysis 
StatView version 5.0.1 software (Windows version; SAS Institute, Cary, NC) 
or GraphPad Prism 5.0 software (GraphPad Prisim Software, Inc., La Jolla, CA) 
were used for all statistical analyses. Comparisons between groups were done 
using Student’s t test or one-way analysis of variance (ANOVA) where 
appropriate. Survival curves were analyzed using the log-rank test. Statistical 
significance was assumed at p<0.05.  
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RESULTS 
1. Exogenous expression of GM-CSF in murine embryonic stem cell ES-
D3. 
The antigenic similarity between embryos and tumors has raised the idea of 
using embryonic material as a prophylactic vaccine against cancer [19, 97, 98]. 
An earlier study reported that a vaccine comprised of allogeneic murine ESCs 
and murine STO fibroblasts expressing GM-CSF to amplify immune responses 
successfully blocked the outgrowth of different lung tumors in mice [29]. 
However, this vaccine is impractical for humans for at least two reasons. First, 
administering intact, live ESCs carries the risk of generating 
embryomas/teratomas in MHC-matched recipients. Second, the use of live 
fibroblasts to produce GM-CSF is unnecessarily complicated. We sought to 
overcome these hurdles by developing an alternative prophylactic vaccine 
comprised of exosomes derived from murine ESCs expressing GM-CSF 
(Figure 2.1). To this end, we first attempted to stably over-express exogenous 
murine GM-CSF in murine ESC cell line ES-D3 (Figure 2.2).   
Previous studies have shown that the cellular elongation factor-1a (EF1a) 
promoter efficiently drives exogenous gene expression in murine ESCs [99, 
100]. Murine GM-CSF cDNA was cloned into the transfection vector pEF1a-
IRES-hrGFP to generate a corresponding GM-CSF expression vector (Figure 
2.2A). This vector expresses both GM-CSF and GFP from the EF1a promoter 
43 
 
with an IRES sequence allowing us to use the expression of GFP as a marker 
to track GM-CSF expression. GM-CSF was stably over-expressed in ES-D3 
cells by transfection. Flow cytometry analysis revealed that both GM-CSF-
expressing and empty vector control ES-D3 cells express GFP at high levels in 
comparison to untransfected parental ES-D3 cells (Figure 2.2B). Once ES-D3 
cells stably over-expressing GM-CSF were acquired, the amounts of GM-CSF 
secreted into the cell culture medium were determined using a murine GM-CSF 
ELISA kit. As shown in Figure 2.2C, the levels of GM-CSF generated by ES-D3 
cells over-expressing GM-CSF were roughly equivalent to those produced by 
GM-CSF-expressing STO fibroblasts employed in an earlier study [29].  
 
 
 
 
 
 
 
Figure 2.1. Strategies to generate vaccines against lung cancer.   
(A) A previously reported vaccine comprised of allogeneic murine ESCs and 
murine fibroblasts expressing GM-CSF to promote immune responses. (B) 
An improved prophylactic vaccine comprised of exosomes derived from 
murine ESCs expressing GM-CSF. 
A 
B 
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Figure 2.2. Exogenous GM-CSF was stably over-expressed in ES-D3 
cells.  
(A) In the schematic diagram of the plasmid for over-expressing murine GM-
CSF in ES-D3 cells, an EF1a promoter drives GM-CSF expression and GFP 
serves as an expression marker. (B) Fluorescence intensity of GFP in GM-
CSF-expressing ES-D3 cells or their empty vector control cells was 
determined by flow cytometry. (C) GM-CSF levels in transfected ES-D3 cells. 
ELISA measurements of GM-CSF concentrations in the medium of the 
indicated cells. The data are shown as mean ± standard deviations (mean ± 
SD) of three experiments, **, p < 0.001; n.s., not significant; ANOVA with 
Tukey’s multiple comparison test.  
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2. Murine embryonic stem cells expressing GM-CSF maintain their 
pluripotency.   
As a cytokine with immunostimulatory function, GM-CSF has been reported to 
promote differentiation of hematopoietic progenitor cells [101]. To ensure that 
expressing GM-CSF in ES-D3 cells had limited effects on their pluripotent 
undifferentiated state, the pluripotency of ES-D3 cells was evaluated using flow 
cytometry to examine expression of multiple markers of pluripotency and 
differentiation. We assessed cellular expression of pluripotency-associated 
markers SSEA-1 and Oct-3/4 along with differentiation-associated marker 
SSEA-4. As shown in Figure 2.3, high expression levels of pluripotency markers 
SSEA-1 and Oct-3/4 were unchanged in GM-CSF-expressing cells compared 
with those in parental and vector control cells, and over 95% of each of parental 
and transfected ES-D3 cells were positive for the expression of SSEA-1 and 
Oct 3/4. Similarly, expression of the differentiation marker SSEA-4 remained at 
low levels in all of the cell lines examined with less than 1% of cells positive for 
SSEA-4 expression. Overall, these data provide evidence that over-expressing 
GM-CSF does not influence the pluripotency of murine ESCs.  
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Figure 2.3. Pluripotency of ES-D3 cells is not affected by GM-CSF 
expression.  
Flow cytometry analysis of the expression of pluripotency and differentiation 
markers (SSEA1, SSEA4 and Oct3/4) in parental, vector control and 
GMCSF-expressing ES-D3 cells. The data shown are representative of three 
independent flow cytometry assays. 
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3. Isolation and characterization of exosomes from murine embryonic 
stem cells. 
An increasing number of studies suggests that exosomes also exhibit 
immunoregulatory and anti-tumor functions [102]. Thus, we reasoned that 
exosomes from ES-DS cells expressing GM-CSF could also possess biological 
activities to regulate immune responses and prevent tumor growth. To this 
purpose, exosomes from ES-D3 cells stably expressing GM-CSF or its empty 
vector were isolated after several steps of centrifugation. Exosomes generated 
by vector control cells and GM-CSF-transfected cells were examined by TEM 
electron microscopy (Figure 2.4A). TEM images revealed that the exosomes 
were comprised of vesicles of variable sizes, a common feature of exosomal 
preparations [103]. Moreover, the diameters of individual vesicles were 30–100 
nM, consistent with earlier reports [104]. Purity of exosomal/microvesicle 
material was indicated by positive western blot signals for different exosomal 
markers, including CD81, Alix and annexin V, flotillin-1 and CD86. Importantly, 
the abundance of exosomal markers was greatly enhanced in ES-D3-derived 
exosomes compared with corresponding whole cell extracts. In contrast, the 
presence of other subcellular compartment markers in exosomes was not 
detected, including (i) endoplasmic reticulum markers – protein disulfide 
isomerase (PDI) and calnexin, (ii) mitochondrial markers – cytochrome C and 
COX IV-subunit IV, and (iii) the cytosolic marker GAPDH, further demonstrating 
the purity of ES-D3-derived exosomal material (Figure 2.4B). To further 
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characterize isolated exosomes from ES-D3 cells, we used a proteomics 
approach to analyze the profile of exosomal proteins. As expected, well-known 
exosomal protein markers, such as CD81, annexin V and Alix, were present in 
exosomes obtained from ES-D3 cells [Table 2.1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 2.4. Characterization of exosomes isolated from ES-D3 cells. 
(A) Exosomes were isolated from ES-D3 cells stably expressing GM-CSF or 
the empty vector. Exosomes were examined by transmission electron 
microscopy. Arrows indicate individual exosomes, scale bar 100 nM. (B) The 
levels of markers for exosomes, endoplasmic reticulum (ER), mitochondria, 
and cytosol in the indicated exosomes and whole cell extracts (WCE) were 
determined by western blot. PDI, protein disulfide isomerase; cyto C, 
cytochrome C. Molecular weight markers (kD) are labeled on the left.  
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Table 2.1. Exosomes derived from ES-D3 cells express prototype 
exosomal markers. 
Exosomal markers in exosomes isolated from ES-D3 cells were identified by 
a proteomics approach. 
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4. The majority of GM-CSF is localized within exosomes.  
As shown earlier (Figure 2.2C), the majority of GM-CSF expressed in ES-D3 
cells was extracellularly secreted. The concentrations of GM-CSF in isolated 
exosomes were investigated by ELISA. A significant amount of GM-CSF was 
detected in the exosomes isolated from ES-D3 cells over-expressing GM-CSF, 
but not in those prepared from vector control cells (Figure 2.5A). To further 
investigate GM-CSF protein localization in the exosomes, we quantitated 
exosomal GM-CSF levels under different experimental conditions through an 
ELISA-based approach (Figure 2.5B). Briefly, the detergent Tween-20 (0.05%) 
was first employed to permeabilize the exosomal membranes, and ELISA 
assays were carried out in buffers with or without 0.05% Tween-20. Since 
Tween-20 is known to reduce protein-protein interactions, the background GM-
CSF levels detected in control exosomes were significantly reduced by Tween-
20 in the washing buffer. In contrast, the amounts of GM-CSF in the exosomes 
isolated from ES-D3 cells expressing GM-CSF were significantly increased by 
Tween-20. This result indicates that Tween-20 permeabilized exosomal 
membrane, making GM-CSF molecules located inside the exosomes available 
for detection. These data suggest that almost all GM-CSF is located in the 
lumen of the exosomes derived from ES-D3 cells.  
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Figure 2.5. GM-CSF is located within the exosomes 
(A) The amounts of GM-CSF in exosomes isolated from vector control ES-
D3 cells or GM-CSF-expressing ES-D3 cells were evaluated by ELISA. The 
data are presented as mean ± SD of three independent experiments. *, 
p<0.05; ANOVA with Tukey’s multiple comparison test. (B) The localization 
of GM-CSF in exosomes was examined. Exosomes pretreated with or 
without 0.05% Tween-20 were added to an ELISA plate. ELISA was carried 
out using washing buffer containing either 1 x PBS only or 1 x PBS + 0.05% 
Tween-20. The data are shown as mean ± SD of three independent ELISA 
experiments. *, p<0.05; ANOVA with Tukey’s multiple comparison test. 
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5. Vaccination with GM-CSF-expressing ESC-derived exosomes prevents 
the outgrowth of implanted lung adenocarcinoma. 
To explore the prophylactic potential of exosomes isolated from ESCs for lung 
cancer, a standard vaccination timing regimen was carried out (Figure 2.6A). 
Specifically, C57BL/6 mice (n = 20) were immunized twice (days 0 and 7) with 
vehicle control, the exosomes of ES-D3 cells expressing empty vector (ES-exo) 
or the exosomes of GM-CSF-expressing ES-D3 cells (ES-exo/GM-CSF). Mice 
were then challenged with subcutaneous (s.c.) inoculation of Lewis lung 
carcinoma (LLC) cells at day 14 and monitored for tumor outgrowth. Robust 
protection against tumor initiation and growth was observed only in mice 
vaccinated with ES-exo/GM-CSF (Figure 2.6B). Vaccination of mice with ES-
exo/GM-CSF was 60% effective in preventing tumor outgrowth, whereas all 
non-vaccinated control animals developed tumors by day 28 post-challenge. 
More importantly, LLC tumors that developed in exo/GM-CSF-vaccinated mice 
(n = 8) were significantly smaller and exhibited greatly reduced tumor growth 
rate compared with non-vaccinated control and ES-exo-vaccinated mice 
(Figure 2.6C). Furthermore, vaccination with ES-exo was completely ineffective 
in reducing tumor outgrowth, revealing an essential role of immune-stimulatory 
GM-CSF for anti-tumor efficacy of the vaccine.  
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Figure 2.6. Vaccinating mice with the exosomes from ESCs expressing 
GM-CSF prevents implanted lung tumor growth.  
(A) Scheme of immunization. Male C57BL/6 mice were immunized twice with 
1 x PBS (control), ES-exo or ES-exo/GM-CSF (Days 0 and 7) prior to s.c. 
challenge with LLC at Day 14. (B) Tumor growth was monitored daily in all 
animals (20 mice/group) until sacrifice due to tumors exceeding 5% of body 
weight. The ES-exo/GM-CSF-vaccinated tumor-free mice remained so for 
up to 4 months later with no overt signs of distress. Results are 
representative of three independent experiments. ***, p < 0.0001; relative to 
control group; log-rank test. (C) Tumor growth was measured with calipers 
every 2nd or 3rd day and tumor volumes were plotted as indicated. The data 
are represented as mean ± SD the average of tumor volumes of (with 20 
mice/ in control group, 8 mice in ES-exo group and 8 mice/in ES-exo/GM-
CSF group and are representative of three independent experiments. **, p < 
0.001; ANOVA with Tukey’s multiple comparison test. 
A B 
C 
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6. Vaccination with ES-exo/GM-CSF has no toxic side effects in mice. 
To evaluate whether any toxic effects are associated with the regimen of two 
weekly vaccinations, we examined fertility, kidney function, liver function, and 
complete blood count (CBC) in vaccinated and unvaccinated mice. For fertility, 
there was no difference in litter sizes between female animals vaccinated with 
ES-exo/GM-CSF and their control counterparts (Figure 2.7A). Moreover, 
vaccination with ES-exo/GM-CSF did not alter the gender ratio of litters (Figure 
2.7B).   
As shown in Figures 2.8A-B, the levels of alanine transaminase (ALT) and 
alkaline phosphatase (ALP) were similar among control, ES-exo and ES-
exo/GM-CSF-vaccinated mice, indicating that liver function remained 
unchanged after vaccination. To assess kidney function, we measured the 
levels of creatinine and blood urea nitrogen (BUN) in serum, and slight changes 
in BUN and creatinine levels between the vaccinated group and control group 
were detected (Figures 2.8C-D). Finally, complete blood count (CBC) analysis 
were carried out (Figures 2.9), showing no significant difference in blood cell 
counts among the mice in different experimental groups. Overall, these studies 
indicate that vaccination with ES-exo/GM-CSF did not induce any toxic effects 
in the immunized mice. 
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Figure 2.7. Vaccination with ESC-derived exosomes (ES-exo/GM-CSF) 
does not reduce fertility of mice.  
Following immunization twice with vehicle control (1 x PBS) or ES-exo/GM-
CSF (days 0 and 7), female C57BL/6 mice were bred with C57BL/6 male 
mice at Day 14. (A)The dot graph showing the litter sizes of unvaccinated 
control or ES-exo/GM-CSF-vaccinate female mice (4 mice in each group) on 
the date of delivery. The average values of litter sizes are also presented. 
n.s., not significant, ANOVA with Tukey’s multiple comparison test. (B)The 
numbers of two genders in each litter 4 weeks following birth. The mean 
values of the numbers of newly born male or female mice is shown (n = 4 
per group, n.s., not significant; ANOVA with Tukey’s multiple comparison 
test). 
B A 
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Figure 2.8. ES-exo/GM-CSF vaccination does not display toxic effects 
on functions of kidney and liver. 
Male C57BL/6 mice were vaccinated twice with vehicle only (control), ES-
exo or ES-exo/GM-CSF (days 0 and 7). The serum was collected from each 
mouse and functions of liver and kidney were evaluated at Day 14. (A-B) 
Liver function was determined by examining the levels of alanine 
aminotransferase (ALT) and alkaline phosphatase (ALP). Bar graph showing 
ALT and ALP levels in serum obtained from mice vaccinated with vehicle only 
(control), ES-exo or ES-exo/GM-CSF. (C-D) Kidney damage was assessed 
by measuring the levels of blood urea nitrogen (BUN) and creatinine. Bar 
graph showing the levels of BUN and creatinine in serum acquired from the 
indicated mice. All of the data are presented as mean ± SD of measured 
values with 4 mice in each group. n.s., not significant, ANOVA with Tukey’s 
multiple comparison test. 
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Figure 2.9. ES-exo/GM-CSF vaccination has no influence on blood cell 
counts. 
Male C57BL/6 mice were immunized twice with vehicle only (control), ES-
exo or ES-exo/GM-CSF (days 0 and 7). At day 14, whole blood was collected 
from each mouse and examined by complete blood count (CBC). Bar graph 
showing the levels of different cell types in blood obtained from the indicated 
mice. The data represent mean ± SD of cell numbers. (n = 4 per group, mean 
± SD; n.s., not significant, ANOVA with Tukey’s multiple comparison test). 
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7. Vaccination with ES-exo/GM-CSF induces tumor cell-specific Th1-
mediated cytokine response in CD8+ T cells.  
We next determined the ability of CD8+ T cells from vaccinated mice to produce 
effector cytokines required for effective anti-tumoral cytolytic activity. These 
experiments were carried out by the laboratory of Dr. Kavitha Yaddanapudi. In 
response to re-stimulation with LLC cell lysate, a significantly higher frequency 
of IFN-- and TNF--producing CD8+ splenocytes were obtained from ES-
exo/GM-CSF- vaccinated mice when compared with the non-vaccinated control 
and ES-exo-vaccinated mice (Figure 2.10). Importantly, analysis of the 
phenotype of tumor-infiltrating immune cells supports the concept that 
vaccination led to an immune-based suppression of tumor growth.  
Using tumors isolated from unvaccinated, ES-exo- and ES-exo/GM-CSF-
vaccinated mice, we found substantial increases in IFN-- and TNF--
producing CD8+ T cells only in mice vaccinated with exosomes prepared from 
GM-CSF-expressing ESCs in response to re-stimulation with LLC lysate 
(Figure 2.11).  
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Figure 2.10. ESC-derived exosome vaccination induces Th1-mediated 
cytokine responses in splenic CD8+ T cells.  
C57BL/6 mice were immunized twice (days 0 and 7) with vehicle only 
(control, 1 x PBS), ES-exo or ES-exo/GM-CSF. Ten days after the boost, 
splenocytes from mice were stimulated with LLC lysate and surface 
expression of CD3, CD8 and intracellular expression of cytokines and 
analyzed by flow cytometry. (A) Dot plots showing IFN- expression in CD8+ 
T cells in splenocyte cultures obtained from the indicated mice. Numbers in 
graphs represent the percentages of each subpopulation. (B, C) Bar graphs 
showing percentages of CD8+IFN-+, and CD8+TNF-+ in splenocyte 
cultures derived from control, ES-exo- or ES-exo/GM-CSF-vaccinated mice. 
Results are expressed as percentages of total cells (n = 6 per group, mean 
± SD, **, p<0.001; ***, p<0.0001; ANOVA with Tukey’s multiple comparison 
test).  
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Figure 2.11. Vaccination with ESC-derived exosomes promotes Th1-
mediated cytokine responses in intratumoral CD8+ T cells.  
Following immunization with vehicle only (control), ES-exo or ES-exo/GM-
CSF twice (days 0 and 7), C57BL/6 mice were challenged with injection of 
LLC (s.c.) on day 14. Tumor-infiltrating cells were collected 15–18 days later 
and stimulated with LLC lysate (50 mg/ml) for 24 hours. Cells were then 
restimulated for 6 hours with LLC lysate (50 mg/ml) in the presence of 
Brefeldin A (1 µL/ml). Surface expression of CD8 and intracellular expression 
of cytokines were evaluated by flow cytometry. The pan-hematopoietic 
marker CD45 was used to identify intratumoral immune cells. (A) Dot plots 
showing IFN- expression in CD45+CD3+CD8+ cells obtained from control, 
ES-exo- or ES-exo/GM-CSF-vaccinated mice. Numbers in graphs represent 
the percentages of each subpopulation. (B, C) Bar graphs showing 
percentages of CD45+CD3+CD8+ IFN-+ (B) and CD45+CD3+CD8+ TNF-α+ 
(C) in tumors derived from the indicated mice. Results are demonstrated as 
percentages of IFN-+ cells or TNF-α+
 
cells in CD45+CD3+CD8+ cells (n = 6 
per group, mean ± SD, *, p<0.05 **, p<0.001; n.s., not significant, ANOVA 
with Tukey’s multiple comparison test). 
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8. Vaccination with GMCSF-expressing ESC-derived exosomes increases 
the ratio of CD8+ T effector cells to Tregs in the tumor.  
Our results so far suggest that ES-exo/GM-CSF vaccine-induced anti-
tumor efficacy is reliant on CD8+ T effector cells. Therefore, Dr. Kavitha 
Yaddanapudi’s group analyzed effects of our vaccination strategy on the 
phenotype of tumor-infiltrating CD8+ T cells and Tregs, a prominent suppressor 
subset that hamper anti-tumoral effector responses. Tumors from controls and 
vaccinated mice (from the small numbers of ES-exo/GM-CSF-vaccinated mice 
that did develop LLC lesions) were harvested and used to investigate the 
subset profiles of tumor-infiltrating immune cells. Flow cytometry analysis 
showed a significant decrease in the percentage of CD4+CD25+Foxp3+ Tregs in 
tumor infiltrates from ES-exo/GM-CSF-vaccinated mice when compared with 
non-vaccinated control and ES-exo-vaccinated mice (Figures 2.12A-B) and the 
ratio of CD8+ T cells to Tregs was significantly increased in the tumor infiltrates 
from ES-exo/GM-CSF-vaccinated mice (Figure 2.12C). Additionally, CD8+ cells 
in the ES-exo/GM-CSF tumor infiltrates had significantly elevated expression 
of the activation marker CD25 (Figure 2.12D).  
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Figure 2.12. ES-exo/GM-CSF vaccination decreases T regulatory (Tregs) 
cells and increases the ratio of effector CD8+ T cells to Tregs in the 
tumors.  
C57BL/6 mice were vaccinated twice (days 0 and 7) with vehicle only 
(control), ES-exo or ES-exo/GM-CSF followed by s.c. inoculation of LLC on 
day 14. Tumor-infiltrating cells were analyzed by flow cytometry 15–18 days 
later using the pan-hematopoietic marker CD45 to distinguish tumor-
infiltrating immune cells from tumor cells. (A) Dot plots showing the 
percentages of Foxp3+ Tregs in tumor-infiltrating CD3+CD4+ cells obtained 
from the indicated mice. Numbers in graphs are the percentages of each 
subpopulation. (B) Bar graphs showing the percentages of Foxp3+ Tregs sub-
populations in tumor-infiltrating CD3+CD4+ cells (n = 4 per group, mean ± 
SD, *, p<0.05; ANOVA with Tukey’s multiple comparison test). (C) Dot graph 
showing the ratio of CD8+Foxp3- to CD8-Foxp3+ cells in 1 of 2 representative 
experiments (n = 4 per group, mean ± SD, *, p<0.05; ANOVA with Tukey’s 
multiple comparison test). (D) ESC-derived exosome vaccination increases 
the frequency of functional CD8+ T cells in tumors. Bar graph showing the 
percentages of CD25+CD8+ in CD45+ tumor-infiltrating cells obtained from 
control and ES-exo/GM-CSF-vaccinated mice. Results are expressed as 
percentages of CD45+ cells. The data represent results from 2 independent 
experiments with 3 mice/group. *, p<0.05; relative to control group; unpaired 
t test. Error bars represent mean ± SD.  
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9. ESC-derived exosome vaccination prevents the outgrowth of an 
implanted mammary carcinoma.  
To test the effectiveness of ES-exo/GM-CSF vaccine in targeting multiple 
cancer types, an additional experiment was performed using the mammary 
carcinoma cell line 4T1, which is syngeneic to the Balb/c mouse strain. Female 
Balb/c mice were divided into vehicle control, ES-exo and ES-exo/GM-CSF 
groups (10 per group) and vaccinated for two weeks (s.c. route). Following 
vaccination, 4T1 cells (1 x 105) were subcutaneously injected (Figure 2.13A). 
Tumor growth assessment by caliper measurement showed significantly lower 
tumor progression in the ES-exo/GM-CSF group (Figure 2.13B). Using 
splenocytes isolated from unvaccinated, ES-exo- and ES-exo/GM-CSF-
vaccinated mice, we found a significant increases in IFN--producing CD8+ T 
cells in mice vaccinated with ES-exo/GM-CSF in response to re-stimulation with 
4T1 lysate (Figure 2.13C, D). 
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Figure 2.13. Vaccination with ES-exo/GM-CSF slows the outgrowth of 
an implanted mammary carcinoma.  
(A) Scheme of immunization. Female Balb/c mice were immunized twice 
(days 0 and 7) with vehicle only (control), ES-exo or ES-exo/GM-CSF before 
s.c. challenge with syngeneic 4T1 cells on day 14. (B) Tumor growth was 
monitored by measuring tumor volumes. The data represent the average 
tumor volumes of 20 mice/group. Error bars represent mean ± SD. (C, D) 
ESC-derived exosome vaccination induces Th1-mediated cytokine 
responses in splenic CD8+ T cells. Splenocytes from vaccinated and control 
mice were co-cultured with 4T1 lysate (50 mg/ml) for 4 days before 
restimulation for 6 hours with 4T1 lysate (50 mg/ml) in the presence of 
Brefeldin A (1 µl/ml). After restimulation, surface expression of CD8 and 
intracellular expression of IFN-g were evaluated by flow cytometry. (C) Dot 
plots showing IFN- expression in CD8+ cells in splenocyte cultures 
obtained from the indicated mice. Numbers in graphs represent the 
percentages of each subpopulation. (D) The data shown in (C) are 
summarized. Results are presented as percentages of IFN--positive cells 
in CD8+ cells (n = 4 per group, mean ± SD, *, p<0.05; ANOVA with Tukey’s 
multiple comparison test). 
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DISCUSSION 
Traditionally, among different approaches of treatment, vaccines are a very safe 
and effective strategy to prevent infectious diseases. However, the utilization of 
vaccination in cancer prevention is limited. The only verified prophylactic anti-
cancer vaccination in clinics is the vaccine against human papilloma virus (HPV) 
that causes the greatest risk for cervical cancer [105]. This is a conventional 
vaccine based on hollow virus-like particles. Unfortunately, most types of 
cancers are not induced by infection. The development of prophylactic vaccine 
against non-infection related cancers is still at early stages.  
Fetal tissues have been reported to prevent transplantable tumors in the 
20th century [18]. In a previous study [29], ESCs along with a source of GM-
CSF have been shown to successfully block the outgrowth of implanted as well 
as carcinogen-induced  lung tumors in mice. To eliminate the risk of teratoma 
formation induced by ESCs, we generated ESCs over-expressing GM-CSF and 
isolated the exosomes from the cells as a vaccine against implanted lung 
tumors in the present study (Figure 2.1). As the effectiveness of embryonic 
materials in tumor prevention is likely to be attributed to their pluripotent 
characteristics shared with cancer cells, we ensured that exogenous 
expression of GM-CSF did not influence the pluripotency of the transfected ES-
D3 cells (Figure 2.3). Furthermore, the exosomes isolated from the ES-D3 cells 
appear to possess high purity without detectable contamination from other 
cellular constituents, such as cytoplasm and organelles (Figure 2.4).  
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As a monomeric glycoprotein cytokine, GM-CSF functions to stimulate the 
development of the immune system, such as activation of 
immune/inflammatory cascades [37]. Earlier studies indicate that GM-CSF by 
itself lack cancer prevention efficacy. In prophylactic setting, an ES cell vaccine 
composed of irradiated allogeneic murine ESCs and GM-CSF-expressing 
murine STO fibroblasts was very effective in preventing lung malignancies [29]. 
Interestingly, STO fibroblasts expressing GM-CSF failed to provide any 
protection against the outgrowth of LLC tumors, suggesting that the observed 
protection with this vaccine is not due to non-specific immune responses 
evoked by GM-CSF [29]. Therefore, it is unlikely that GM-CSF molecules in the 
exosomes in ES-exo/GM-SCF vaccine are solely responsible for anti-tumor 
immunity. 
In our research, exosomes isolated from ESCs expressing GM-CSF could 
be used as a vaccine for the prevention of transplanted lung tumor outgrowth 
compared with the exosomes isolated from vector control cells (Figure 2.6). In 
those animals that did develop tumors, tumor growth was significantly slower 
when compared to unvaccinated control animals and those vaccinated with the 
exosomes from ESCs lacking GM-CSF expression. In the latter group of 
animals, tumor outgrowth did not differ from that detected in unvaccinated mice. 
These findings indicate that GM-CSF is a potent stimulator of immune 
responses during vaccination, which is in agreement with earlier reports [29, 
106]. Indeed, the immunostimulatory property of GM-CSF has been recently 
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exploited by Bencherif et al. for amplification of immune responses in a 
melanoma model [107].  
In our experimental tumor model, ES-exo/GM-CSF combination vaccine 
significantly increases the ratio of CD8+ T cells to Tregs and the percentages of 
CD8+CD25+ and CD8+IFN-+ effector cells within the tumors, suggesting 
effective vaccine-induced, tumor-reactive immune system priming. These 
immunophenotyping data lend additional support to the tentative conclusion 
that such vaccination might be a viable approach to the prevention of cancers 
in humans. Interestingly, the majority of detected GM-CSF was located inside 
exosomes (Figure 2.5). Therefore, as an effective immunogen, the immunologic 
activation by GM-CSF likely arises from exosomal fusion with the plasma 
membrane of antigen-presenting cells.  
The underlying mechanisms of the cancer-preventive efficacy of ES-
exo/GM-CSF vaccination are not fully understood. It is highly likely that 
exosome-based vaccine elicits similar immune responses as its intact cell-
based counterpart [29]. Anti-tumor immunity evoked by ES-exo/GM-CSF 
vaccination may be attributed to an increase in an effective repertoire of CD8+ 
cytotoxic T cells, enhanced infiltration of CD8+ T cells into the tumor 
microenvironment, and decreased tumor suppressive Tregs in tumors.   
Extracellular vesicles (EVs) range in size from 20 nm to 200 nm in diameter 
[55]. Exosomes, a subtype of EVs, are membrane vesicles with variable size of 
30–100 nm in diameter. In Figure 2.4A, TEM images revealed that the sizes of 
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vesicles in our samples were consistent with those of exosomes reported 
previously. Purity of exosomal preparations was further demonstrated by 
western blot analysis (Figure 2.4B), indicating the predominant presence of 
exosomes in our samples. Due to overlapping molecular markers between 
exosomes and other types of EVs, we could not completely exclude the 
possibility of small amounts of EVs other than exosomes existing in our 
preparations [90]. Additional experimental approaches, such as immunogold 
TEM staining [108] and nanoparticle tracking analysis [109], could be utilized 
to further characterize exosomal preparations from ESCs. 
Exosomes, initially defined as cell-derived nanovesicles, were first 
described in 1946 when they were isolated from platelets [56]. Recently, 
evidence has emerged that exosomes could stimulate immune responses in 
cancer treatment [87]. The exosome-based anti-cancer therapies have high 
stability, in vivo bioavailability, and an inherent ability to stimulate anti-tumor 
immune responses. Exosomes do not endogenously replicate, as whole cells 
do, and exosomes can be readily bioengineered to a clinical grade and scaled 
up for dosing requirements [91]. The idea of using tumor-derived exosomes as 
a vaccine has been proposed earlier [110], although this approach is 
complicated by the fact that such preparations may also be strongly 
immunosuppressive. Furthermore, tumor cells expressing GM-CSF have been 
explored to serve as a therapeutic vaccine with variable success in certain 
animal models [111, 112]. In pre-clinical studies, exosomes obtained from 
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matured dendritic cells (DCs) express more abundant MHC-I and MHC-II 
molecules as well as co-stimulatory molecules (e.g., CD40, CD80, and CD86) 
and induce potent antigen-specific anti-tumor T effector responses shown by 
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells both in vitro and in 
vivo [71, 113, 114]. Similarly, the exosomes isolated from ESCs comprises 
stable vesicles harboring protein contents that can be tailor-manufactured from 
human cell lines in clinical grade (cGMP) quality [91]. Furthermore, ES-derived 
exosomes can be produced in large quantities and cryo-preserved for more 
than 6 months at −80 °C with their functional activity intact [103].  
As a promising biological agent to prevent the outgrowth of lung cancer, 
exosomes from ES-D3 cells expressing GM-CSF need to exhibit limited toxic 
effects associated with the vaccination. Usually, the side effects of a biological 
immune modulator or biological agent are different from conventional drugs 
[115], and they are always linked to the biological effects induced by the agent. 
There are five types of reactions of the adverse side-effects from biological 
agents, including cytokine related syndrome, immediate and delayed 
hypersensitivity reactions, immune imbalance syndrome, cross-reactions on 
different tissues and non-immunological side-effects [116]. Particularly, these 
reactions can be partially reflected from biological evaluations, such as CBC, 
liver and kidney functions. Indeed, we did not observe any significant changes 
in biological functional parameters between vaccinated and unvaccinated 
animals, indicating that ES-exo/GM-CSF is a safe vaccination strategy without 
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detectable side effects (Figure 2.7-9). 
In our studies, ES-exo/GM-CSF immunization elicited immunologic 
rejection of transplantable tumors (Figure 2.6). This raised a concern that the 
vaccination strategy might have deleterious effects on fertility of vaccinated 
female mice, as embryos could be eliminated by the immunity generation by 
vaccine. As shown in Figure 2.7, ES-exo/GM-CSF vaccine exerted little 
influence on the fertility of female mice. This could be explained by the 
difference in antigen repertoires between mouse embryos and exosomes from 
ESCs. As a result, vaccination with ES-exo/GM-CSF confers limited cross-
immunity to embryos. In addition, maternal immune tolerance, the immune 
tolerance towards the semi-allogeneic conceptus during pregnancy, is also 
involved in protecting embryos from being rejected. Emerging evidence indicate 
that a number of immunosuppressive factors produced by placenta are crucial 
for maternal-fetal tolerance. Among them, placenta-derived exosomes bearing 
human ligands of activating NK cell receptor NKG2D have been found to 
promote the fetal immune escape by decreasing the cognate receptor 
expression in a variety of immune cells [117]. 
The effects of aging on the immune system are well documented, as the 
age of patients has great impacts on the immune responses and the outcomes 
of treatment against lung cancer [118, 119]. Consequently, elderly lung cancer 
patients generally do not respond to immunotherapy as well as younger 
patients. In our study, we investigated the cancer prevention efficacy of 
74 
 
exosome-based vaccine in mice at young age. In the future, animals with 
different ages will be studied to evaluate how aging might influence the 
vaccination efficacy of ES-exo-GM-CSF.  
Finally, a recent publication shows that human and murine induced 
pluripotent stem cells (iPSCs) express tumor-associated antigens, and that 
irradiated autologous iPSCs, in a prophylactic setting, prevent tumor growth in 
syngeneic murine breast cancer, mesothelioma, and melanoma models [30]. 
This study provides further support to our vaccination strategy utilizing 
exosomes from GM-CSF-expressing ES-D3 cells as an effective immune-
preventive lung cancer vaccine. 
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 CHAPTER III 
MURINE ESC-DERIVED EXOSOMES FUNCTION AS A CELL-FREE 
VACCINE AGAINST METASTASIZED LUNG CANCER 
 
INTRODUCTION 
It is well established that the immune system plays an essential role in lung 
cancer therapy. Lung cancer cells are known to elicit suppressive immune 
response by releasing cytokines such as interleukin 10 (IL-10) and transforming 
growth factor β (TGF-β) [120]. In the tumor microenvironment, tumor cells also 
express regulatory molecules to increase tumor-suppressive immune cell 
populations, such as T regulatory cells (Tregs), and enable tumors to escape 
from the immune system [121]. Immunotherapeutic strategies are generally 
considered to display less unwanted toxicity compared with other types of 
cancer treatment. The development of anti-cancer immunotherapy is 
progressing in antigen-specific or antigen-nonspecific branches. Currently, the 
most promising immune therapy is the immune checkpoint inhibitors by 
blocking programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte 
antigen 4 (CTLA-4) [122]. However, neoplastic cells are capable of escaping 
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from immune surveillance through the inhibitory feedback loops, including the 
PD-1 pathway. Particularly, the efficacy of checkpoint inhibitors to suppress lung 
cancer, especially advanced or metastatic non-small cell lung cancer (NSCLC) 
is modest [123].   
A prophylactic cancer vaccine is a promising choice to reduce pulmonary 
malignancy. The majority of cancer vaccines under development usually need 
robust adjuvants to enhance the immune response because most of the tumor 
antigens targeted in vaccines are identical to “self“ antigens [124]. However, the 
efficacy of a lung cancer vaccine will be markedly increased if the vaccine 
targets multiple “non-self” antigens presented only by lung tumors. Emerging 
evidence has demonstrated that tumor cells and embryonic stem cells (ESCs) 
share common antigens that are considered as “non-self” antigens, because 
they are not expressed in normal adult tissues [18]. Based on the antigenic 
similarity between malignant cells and ESCs, researchers have developed an 
prophylactic lung cancer vaccine composed of irradiated, intact murine ESCs 
and murine fibroblasts expressing the immunostimulatory adjuvant 
granulocyte-macrophage colony stimulating factor (GM-CSF) [29]. In support 
of cancer prevention capability of ESCs, a recent study has demonstrated that 
irradiated, induced pluripotent stem cells (iPSCs) along with the adjuvant CpG 
function as a tumor vaccine to elicit an anti-tumor response against 
transplanted breast cancer, mesothelioma and melanoma [30].  
Despite the promise of ESC-based vaccine to evoke anti-lung cancer 
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immune responses, such a vaccine has two obvious challenges to overcome 
for human application, First, the administration of intact ESCs, albeit irradiated, 
raises the risk of embryoma/teratoma formation. Furthermore, it is 
unnecessarily complicated to use fibroblasts as a source for the adjuvant GM-
CSF. To overcome these hurdles, we have developed an alternative 
prophylactic vaccine comprised of exosomes from murine ESCs engineered to 
produce GM-CSF (ESC-exo/GM-CSF). This self-contained, relatively stable 
exosome-based vaccine significantly slowed or blocked the outgrowth of 
subcutaneously implanted lung tumors (Figure 2. 6).  
Metastasis results from the tumor cells on primary sites migrating to distant 
organs. The process of metastasis includes cancer cell proliferation, 
angiogenesis, cell adhesion, migration, and invasion into the surrounding tissue 
[125]. The prognosis of cancer patients decreases dramatically once 
metastasis happens [126]. Despite ongoing progress in diagnosis and patient 
care, metastasis is still the principal cause of mortality from neoplastic diseases. 
Lung metastasis occurs when malignant cells originating in another organ of 
the body migrate to and establish in the lung. Chemotherapy is the most 
commonly used therapy for lung metastasis with modest efficacy [127]. 
Therefore, if malignant cells metastasizing to the lung could be recognized by 
the immune system and eliminated before their establishment and growth in the 
lung, it would have promising application in clinics.  
In this study, we show that ES-exo/GM-CSF vaccination effectively 
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prevents the outgrowth of metastasized lung tumors in mice. Notably, the anti-
tumor efficacy of this vaccination strategy is associated with reduced tumor-
promoting immune cells and increased tumor-suppressing immune cells in lung 
metastases. Overall, our research provides a strategy for developing a cell-free 
preventative vaccine against metastasized lung tumors.
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MATERIALS AND METHODS 
1. Mice 
Female C57BL/6 mice (8 weeks of age) were purchase from Jackson 
Laboratory (Bar Harbor, ME) and housed at the University of Louisville 
Research Resources Facilities (RRF) under standard conditions. Mice were 
handled in accordance with the American Association for the Accreditation of 
Laboratory Animal Care (AAALC) guidelines and the "Guide for the Care and 
Use of Laboratory Animals" (Institute of Laboratory Animal Resources, National 
Research Council, National Academy Press, 1996). The mouse study was 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Louisville (protocol number: 18301). 
2. Vaccination and tumor challenge  
Exosomes from ES-D3 cells were acquired as described in “MATERIALS AND 
METHODS” section of Chapter 2. Female C57BL/6 mice (8 weeks of age) were 
immunized twice (days 0 and 7) with vehicle only (1 x PBS), 225 µg exosomes 
isolated from ES-D3 cells expressing the empty vector (ES-Exo) or 225 µg 
exosomes isolated from ES-D3 cells stably-expressing GM-CSF (ES-Exo/GM-
CSF). Exosomes were injected subcutaneously (s.c.) in the right flank of mice. 
Following vaccination, mice were challenged with LLC cells (0.15 ᵡ 106) by tail 
vein injection on day 14. Immuno-analysis of splenocytes and tumor-infiltrating 
lymphocytes were carried out 5 weeks following LLC cell challenge. Lung 
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tumorigenesis was examined 6 or 7 weeks after LLC cell injection.  
3. Histological analysis of lung tissues 
Lung tissue sections were prepared as previously described with some 
modifications [128]. Briefly, lung tissues were fixed in 10% neutral phosphate 
buffered formalin for 24 hours at room temperature. After paraffin processing 
(TEK VIP; Sakura Finetek; Torrance, CA) and embedding (EG1160; Leica 
Biosystems; Buffalo Grove, IL), paraffin microtomy (RM2135; Leica Biosystems) 
was performed at 5 microns thickness of slide for each section. 3 sections were 
processed with 50 microns between each. For each biopsy core, three 
consecutive sections are placed on 3 slides (total of 9 sections per lung tissue) 
to assure detection of tumorigenesis in a whole lung. Slides of sections were 
deparaffinized and rehydrated in xylene, ethanol and deionized water. Slides 
were stained in hematoxylin (95057-844; VWR; Radnor, PA). After rinsing with 
deionized water, the slides were stained by eosin (HT110232; Thermo Fisher) 
and dehydrated in ethanol and xylene. Coverslips were mounted on slides by 
xylene-based permountTM mounting medium (SP15-500; Thermo Fisher; 
Waltham, MA). Finally, the slides were dried overnight in a chemical hood. The 
slides were scanned by Aperio Imagescope (Leica Biosystems) and analyzed 
with the software (version 12.3.3).  
4. Antibodies for immune-analysis 
Antibodies used for evaluating splenocytes and tumor-infiltrating lymphocytes 
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were: anti- CD3 mAb (clone 17A2, 100222); anti-CD4 mAb (clone GK1.5; 
100406); anti-CD8 mAb (clone 53-6.7; 100712); anti-CD11b mAb (clone M1/70; 
101228); anti-Ly6C mAb (clone HK1.4; 128006); anti-Ly6G mAb (clone 1A8; 
127608); anti-CD16/CD32 mAb (clone 2.4G2; 101320) from Biolegend (San 
Diego; CA), anti-CD44 mAb (clone IM7; 17-0441-82); anti-CD25 mAb 
(clone PC61.5; 45-0251-82) from (Thermo Fisher), anti-CD62L mAb (clone 
MEL-14; 553152; BD Biosciences; San Jose, CA).  
5. Immuno-analysis of splenocytes   
Five weeks following tail vein injection of LLC cells into female C57BL/6 mice, 
spleens were resected and splenocytes were acquired. Single splenocyte 
suspensions were stained with the indicated antibodies for 30 minutes after 
blocking with CD16/CD32 antibody for 15 minutes at 4 °C. After washing, cell 
surface and intracellularly stained cells were analyzed on a FACSCalibur 
(Becton Dickinson; Franklin Lakes, NJ) and results were analyzed using FlowJo 
software (TreeStar, Inc., Ashland, OR).  
6. Immuno-analysis of tumor-infiltrating immune cells 
Vaccinated and control mice with LLC tumors metastasized to lungs were 
euthanized 35 days after tumor challenge. Lungs were resected and 
metastasized LLC tumors were dissected and chopped into small pieces before 
incubation with a mixture of enzymes dissolved in HBSS, including collagenase 
type IV (400 U/ml; C9891; Sigma-Aldrich; St. Louis, MO), hyaluronidase (0.025 
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mg/ml; H6254; Sigma-Aldrich) and DNase I (0.01 mg/ml; D5025; Sigma-Aldrich) 
for 2 hours at 37°C with occasional shaking. The resultant cells were washed 
and passed through a Ficoll gradient (17144002; GE Healthcare; Chicago, IL) 
to eliminate dead cells. Tumor-infiltrating lymphocytes (TILs) were then 
analyzed by flow cytometry for the expression of markers for different immune 
cells. Anti-CD45 antibody was used to selectively exclude CD45− tumor cells 
from analysis so that only CD45+ immune cells were evaluated. The same 
number of cells (based on side-scatter and forward-scatter analyses) was 
acquired in all samples. Respective antibodies specific for the makers were 
used to quantitate the abundance of different immune cell types. T regulatory 
cells (Tregs; Foxp3+) were analyzed using the anti-mouse Foxp3 staining kit (00-
5523-00; Thermo Fisher).   
7. Intracellular cytokine staining 
To evaluate TNF-α and IFN-γ production, TILs were harvested and 
restimulated for 6 h with the LLC lysate (50 μg/ml) in the presence of Golgiplug 
(555029; BD Biosciences) at a concentration of 1 μl/ml of culture medium. After 
restimulation, cells were harvested, Fc receptors were blocked using anti-
CD16/CD32 antibodies, and cells were stained for surface expression of CD8 
and intracellular expression of cytokines using Cytofix/Cytoperm kit (555029; 
BD biosciences) according to the manufacturer’s instructions and analyzed by 
flow cytometry.  
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8. Statistical analysis 
The statistical analysis was carried out using StatView version 5.0.1 software 
(Windows version; SAS Institute, Cary, NC) or GraphPad Prism 5.0 software 
(GraphPad Prisim Software, Inc., La Jolla, CA). Comparisons between 
experimental groups were conducted using Student’s t test or one-way analysis 
of variance (ANOVA) where P value < 0.05 was considered significant. 
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RESULTS 
1. Vaccination with ES-exo/GM-CSF inhibits metastasized lung tumor 
growth 
Metastatic lung cancer is one of the leading causes of death worldwide. As a 
low immunogenic cancer, it is resistant to the surveillance of the immune 
system [129, 130]. In our earlier studies, a prophylactic vaccine comprised of 
exosomes derived from murine ESCs engineered to produce GM-CSF (ES-
exo/GM-CSF) significantly slowed or blocked the outgrowth of subcutaneously 
implanted LLC (Figure 2.6). To evaluate the efficacy of ES-exo/GM-CSF 
vaccine in preventing metastasized lung tumor development, a mouse model 
of experimental pulmonary metastasis was investigated., In this model, tumor 
cells are first injected into the tail vein then reach the lung through blood 
circulation, where tumors are established [131].  
Following a standard immunization timing regimen, C57BL/6 mice were 
vaccinated at day 0 and again on day 7 with 1 x PBS (vehicle control), 
exosomes alone (ES-exo) or GM-CSF-containing exosomes (ES-exo/GM-CSF) 
through subcutaneous (s.c.). injection (Figure 3.1A). Mice were then challenged 
with tail vein inoculation of LLC cells (0.15 x 106) at day 14. In this experimental 
model, LLC tumors were established in the lung 5 weeks following LLC 
challenge.  
To rigorously examine the vaccination efficacy of ES-exo/GM-CSF on 
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metastasized LLC tumors, we carried out two independent experiments to 
examine the status of lung tumors generated by metastasized LLC cells 6 
weeks or 7 weeks following initial LLC cell administration. Immediately after 
collecting lung tissues from the mice in 3 experimental groups, we first counted 
the numbers of tumor nodules on lung surface [132], as a lung tumor nodule is 
defined as a discrete, well-defined, rounded opacity that is completely 
surrounded by lung tissue (Figure 3.1B). The results of lungs acquired 6 weeks 
after LLC inoculation are similar to those obtained 7 weeks post LLC injection 
(Figure 3.1C). Examination of resected lungs revealed that the numbers of lung 
tumor nodules in mice vaccinated with ES-exo/GM-CSF were significantly 
smaller than those in mice injected with vehicle control. The majority of PBS-
administered mouse lungs had surface tumors (8 out of 9 for 6-week group; 10 
out of 11 for 7-week group) with an average of about 3.5 lesions for each mouse. 
In contrast, mice vaccinated with ES-exo/GM-CSF only had an average of 0.5 
lung tumors/mouse (6-week group) or 1.4 lung tumors/mouse (7-week group), 
indicating that immunization with ES-exo/GM-CSF inhibited the metastasized 
lung tumor development. The average tumor nodule number in mice vaccinated 
with ES-exo was higher compared with ES-exo/GM-CSF-immunized mice, but 
the difference was not significant due to variations among the mice in each 
group.   
To further investigate the efficacy of this vaccination strategy, total lung 
tumor mass of metastasized LLC was evaluated by a histological approach. 
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Serial sections were produced from each lung resected from the mice, stained 
with hematoxylin and eosin (H&E) and analyzed by measuring the tumor lesion 
areas in each lung tissue (Figure 3.1D). Typical lung sections from mice showed 
a striking difference between PBS-inoculated mice versus those receiving ES-
exo/GM-CSF vaccination. Numerous large tumor lesions were detected in non-
vaccinated control mouse lung sections, whereas vaccinated animals were 
almost absent of any detectable lesions (Figure 3.1D). The tumor burden was 
calculated as the percentage of lung area occupied by tumor lesions in each 
slide. As shown in Figure 3.1 E, ES-exo/GM-CSF-vaccinated mice had a 
significantly smaller percentage of tumor-bearing lung area compared with the 
mice in unvaccinated control (1x PBS) group or the mice vaccinated with 
exosomes without GM-CSF (ES-exo). Absence of metastasized lung tumors in 
mice immunized with ES-exo/GM-CSF provides evidence that ES-exo/GM-
CSF suppresses the development of metastasized lung malignancy, which is in 
agreement with our earlier studies with subcutaneously implanted LLC tumors 
(Figure 2.6).  
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Figure 3.1. ES-exo/GM-CSF vaccination inhibits the outgrowth of 
metastasized lung tumors.  
(A) The scheme of vaccination is depicted. Female C57BL/6 mice were 
immunized twice (Days 0 and 7) with vehicle control (1 x PBS), exosomes  
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isolated from vector control ES-D3 cells (ES-exo) or exosomes isolated from 
GM-CSF-expressing ES-D3 cells (ES-exo/GM-CSF) prior to tail vein 
injection with LLC cells (0.15 ᵡ 10
6
) on Day 14. Lung tumor development was 
examined 6 weeks or 7 weeks after LLC injection. (B) Representative 
images of lungs resected from euthanized mice. Surface tumor nodules 
were indicated by arrows. Scale bar, 0.5 cm. (C) Surface tumor nodules of 
resected lungs were enumerated by inspection. The data are presented as 
a dot graph of the number of surface tumor nodules of lungs. In the 
experiments carried out 6 weeks after LLC injection, 10 mice in each group. 
In the studies performed 7 weeks following LLC challenge, 11 mice in control 
group, 9 mice in ES-exo group and 10 mice in ES-exo/GM-CSF group. *, p 
< 0.05; **, p < 0.01; ANOVA with Tukey’s multiple comparison test. (D) The 
histological sections of resected lungs were examined by H&E staining. 
Representative images of lung sections are shown (magnification: x 200). 
Lesions on lung sections are indicted by arrows. Scale bar, 500 µM. (E) The 
tumor lesion areas of each lung tissue sections were measured. The 
percentage of total lung area taken up by lung tissues was quantified from 
measurements on H&E sections of resected lungs from animals in each 
group. For each lung, the average value of 3 sections with 50 microns apart 
was calculated. *, p < 0.05; **, p < 0.01; ANOVA with Tukey’s multiple 
comparison test. 
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2. ES-exo/GM-CSF vaccination decreases T regulatory cells (Tregs) in lung 
metastases.  
It is generally believed that immune cells infiltrating into tumor tissues play 
essential roles in tumor development and progression [133]. Importantly, tumor-
infiltrating immune cells are involved in cancer prevention efficacy of a vaccine 
composed of intact ESCs and STO fibroblasts expressing GM-CSF [29]. As 
shown in Figure 3.1, a limited number of mice vaccinated with ES-exo/GM-CSF 
did develop LLC lesions in the lung. To elucidate the underlying mechanisms of 
the immunity against metastasized lung cancer by ES-exo/GM-CSF 
vaccination, Dr. Kavitha Yaddanapudi’s laboratory analyzed the phenotypes of 
tumor-infiltrating immune cells by examining the expression of different immune 
cell markers. Pan-leukocyte marker CD45 was studied to ensure that only 
CD45+ immune cells in tumor infiltrates were examined. 
T cells are known to play an important role in immune responses arising 
during malignancy. Among them, cytotoxic T cells (Tc) have the capability to kill 
a variety of neoplastic cells, whereas immunosuppressive T regulatory cells 
(Tregs) contribute to the development and progression of many cancer types by 
reducing effector cell responses [134, 135]. Therefore, we first analyzed the 
effects of our vaccination strategy on tumor-infiltrating Tc and Tregs. As shown in 
Figures 3.2A and 3.2B, immunization with ES-exo/GM-CSF failed to affect 
intratumor CD8+ Tc levels. However, flow cytometry analysis revealed a 
significant decrease in the percentage of Foxp3+ Tregs in CD4+ T helper cells of 
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tumor infiltrates from ES-exo/GM-CSF-vaccinated mice when compared with 
non-vaccinated control mice (Figures 3.2C-D).  
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Figure 3.2. Vaccination with ES-exo/GM-CSF decreases T regulatory 
cells (Tregs) in metastasized lung tumors. 
Female C57BL/6 mice were vaccinated twice (days 0 and 7) with 1 x PBS 
(control) or ES-exo/GM-CSF prior to tail vein injection with LLC on day 14. 
Five weeks following LLC challenge, lung tumors were resected, digested 
by enzymes, and tumor-infiltrating cells were harvested and analyzed by 
flow cytometry. The pan-hematopoietic marker CD45 was used to identify 
intratumoral immune cells. (A) The presence of tumor-infiltrating cytotoxic T 
cells (Tc) was examined and the percentages of CD8+ Tc cells in CD3+ T cell 
population were determined. (B) Bar graphs showing average of 
percentages of tumor-infiltrating CD8+ Tc cells in CD3+
 
T cells. Four mice in 
control group, and six mice in ES-exo/GM-CSF group. Mean ± SD, n.s., not 
significant; ANOVA with Tukey’s multiple comparison test. (C) Tumor-
infiltrating Foxp3+ Tregs in CD3+
 
CD4+ T cells obtained from control and ES-
exo/GM-CSF-vaccinated mice were evaluated. Numbers in the plots 
represent the percentages of subpopulations. (D) Summary of the data 
shown in (C). (n=4 in control group, n=6 in ES-exo/GM-CSF group; mean ± 
SD, *, p < 0.05; ANOVA with Tukey’s multiple comparison test). 
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3. Vaccination with ES-exo/GM-CSF suppresses tumor-infiltrating 
myeloid derived suppressor cells (MDSCs). 
In addition to Tregs, myeloid-derived suppressor cells (MDSCs) are another 
prominent suppressor class hampering anti-tumoral effector responses [136].  
To elucidate the immunomodulatory influences of ES-exo/GM-CSF vaccination, 
we first evaluated the abundance of CD11b+ immune cells in lung metastases 
with the help of Dr. Kavitha Yaddanapudi. The presence of CD11b+ MDSC in 
tumor-infiltrating non-T (CD3-) and non-B (CD19-) immune cells was 
significantly reduced from 80.7% to 34.9% (Figure 3.3A). As a heterogeneous 
population of immature myeloid cells, MDSCs are composed of the monocytic 
subset (M-MDSCs) and granulocytic subset (G-MDSCs), both of which display 
immune-suppressive capability to promote tumor development. To further 
explore the effects of ES-exo/GM-CSF vaccination on intratumoral MDSCs, we 
examined the presence of MDSC subsets in metastasized lung tumors. As 
shown in Figure 3.3C, the percentage of tumor-infiltrating Gr-1+ G-MDSCs in 
CD11b+ non-T and non-B immune cells was significantly decreased from 49.5% 
to 15.5% in mice vaccinated with ES-exo/GM-CSF and challenged with LLC 
cells when compared with non-vaccinated, LLC challenged control mice. In 
contrast, ES-exo/GM-CSF vaccination did not reduce the percentage of Gr-1low 
M-MDSCs in lung metastases, suggesting that different subclasses of 
intratumoral MDSCs play distinct role in anti-tumor efficacy of ES-exo/GM-CSF 
vaccination. 
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Figure 3.3. Vaccination with ES-exo/GM-CSF suppresses tumor-
infiltrating MDSCs  
Female C57BL/6 mice were vaccinated with 1 x PBS or ES-exo/GM-CSF 
twice (days 0 and 7) and challenged by tail vein inoculation LLC one week 
later. Myeloid derived suppressor cells (MDSCs) infiltrating into lung tumors 
were examined 5 weeks after LLC injection. Intratumoral immune cells were 
identified by CD45, a pan-hematopoietic marker. (A) Dot plots showing the 
abundance of CD11b+ cells in tumor-infiltrating non-T (CD3-) and non-B 
(CD19-) immune cells obtained from control and ES-exo/GM-CSF-
vaccinated mice. The percentages of the individual subpopulation are 
shown. (B) The data shown in (A) are summarized with 4 mice in control 
group, 6 mice in ES-exo/GM-CSF group. Mean ± SD, **, p < 0.001; ANOVA 
with Tukey’s multiple comparison test. (C) Gr-1high granulocytic myeloid 
derived suppressor cells (G-MDSCs) and Gr-1low Monocytic myeloid derived 
suppressor cells (M-MDSCs) in CD11b+ populations shown in (A) were 
examined. The percentages of each subpopulation are indicated in the 
graphs. (D-E) Bar graphs show the summarized data presented in (C). (n = 
4 in control group, n = 6 in ES-exo/GM-CSF group; mean ± SD; ***, p < 
0.0001; n.s., not significant; ANOVA with Tukey’s multiple comparison test). 
95 
 
4. Vaccination with ES-exo/GM-CSF reduces the percentage of 
macrophages in metastasized lung tumors. 
As an integral component of tumor microenvironment, intratumoral 
macrophages are associated with initiation as well as progression of various 
malignancies [137]. The influence of vaccination with ES-exo/GM-CSF on 
tumor-infiltrating macrophages was investigated by Dr. Kavitha Yaddanapudi. 
Previous studies demonstrate that the cell surface protein F4-80 is a major 
marker of murine macrophages [138]. As shown in Figure 3.4A, the abundance 
of F4-80+Gr-1- macrophages in intratumoral CD11b+ non-T and non-B immune 
cells was significantly decreased from 15.8% to 3.06% in ES-exo/GM-CSF-
vaccinated mice compared with non-vaccinated mice inoculated with the 
vehicle control. The CX3CR1+ subpopulation of macrophages has been shown 
to play a central role in lung cancer growth and metastasis via CX3CR1 
signaling [139]. However, the percentage of tumor-infiltrating CX3CR1+ 
macrophages was not significantly influenced by vaccination with ES-exo/GM-
CSF (Figure 3.4D), suggesting that the involvement of distinct subpopulations 
of intratumoral macrophages in the immune responses to ES-exo/GM-CSF 
vaccination is different.  
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Figure 3.4. Vaccination with ES-exo/GM-CSF reduces tumor-infiltrating 
macrophages.  
The vehicle control (1 x PBS) or ES-exo/GM-CSF was injected into female 
C57BL/6 mice twice with 7 days apart, followed by tail vein inoculation of 
LLC 7 days later. The presence of tumor-infiltrating macrophages was 
analyzed by flow cytometry 5 weeks after LLC injection. CD45, as a pan-
hematopoietic marker, was analyzed to evaluate intratumoral immune cells. 
(A) The percentages of F4-80+GR-1- macrophages in intratumoral non-T 
(CD3-) and non-B (CD19-) immune cells from control and ES-exo/GM-CSF-
vaccinated mice are shown. Numbers in the plots represent the percentages 
of each subpopulation. (B) Bar graphs showing the average of percentages 
of F4-80+GR-1- macrophages obtained from control and ES-exo/GM-CSF-
vaccinated mice (n=4 in control group, n=6 in ES-exo/GM-CSF group; mean 
± SD, **, p < 0.001; ANOVA with Tukey’s multiple comparison test). (C) Dot 
plots representing the abundance of CX3CR1+ macrophage subset in 
tumor-infiltrating general macrophage populations shown in (A). The 
percentages of the individual subpopulation are indicated. (D) The data 
shown in (C) are summarized with 4 mice in control group, 6 mice in ES-
exo/GM-CSF group. Mean ± SD, n.s., not significant; ANOVA with Tukey’s 
multiple comparison test. 
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5. ES-exo/GM-CSF vaccination promotes intratumoral B cell populations.  
Emerging evidence has demonstrated that tumor-infiltrating B cells play a 
critical role in tumor development at all stages of lung tumorigenesis [140]. To 
test the effect of ES-exo/GM-CSF vaccination on the levels of B cell populations 
in metastasized lung tumors, Dr. Kavitha Yaddanapudi’s group evaluated the 
presence of CD19+ B cells in intratumoral cells positive for CD45. As shown in 
Figure 3.5, the percentage of CD19+ B cells in tumor-infiltrating CD45+ immune 
cells was significantly increased from 11.1% to 38.1% in mice vaccinated with 
ES-exo/GM-CSF and challenged with LLC cells than their non-vaccinated 
control counterparts. 
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Figure 3.5. ES-exo/GM-CSF vaccination promotes tumor-infiltrating B 
cells against lung metastases. 
Female C57BL/6 mice were vaccinated twice (days 0 and 7) with vehicle 
only (1 x PBS) or ES-exo/GM-CSF followed by LLC challenge through tail 
vein 7 days later. After 5 weeks, cells infiltrating into lung metastases were 
harvested and evaluated using the pan-hematopoietic marker CD45 to 
distinguish tumor-infiltrating immune cells from malignant cells by a flow 
cytometry analysis. (A) Dot plots showing the percentages of CD19+ B cells 
in CD45+ intratumoral cells obtained from control and ES-exo/GM-CSF-
vaccinated mice. Numbers in the dot plots are the percentages of each 
subpopulation. (B) Bar graphs showing average of percentages of CD19+ B 
cells in tumor-infiltrating CD45+ cells acquired from control and ES-exo/GM-
CSF-vaccinated mice with 4 mice in control group, 6 mice in ES-exo/GM-
CSF group. Mean ± SD, **, p < 0.001; ANOVA with Tukey’s multiple 
comparison test. 
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6. Intratumoral Th1 and Th17 effector cells are not affected by ES-exo/GM-
CSF vaccination.  
It is well known that tumor-infiltrating CD4+ effector T cells play critical roles in 
malignancies. Among them, Th1 and Th17 subsets of CD4+ cells are deeply 
associated with pulmonary tumorigenesis [141, 142]. To investigate whether 
ES-exo/GM-CSF vaccination affects the presence of Th1 or Th17 populations 
in metastasized lung tumors, Dr. Kavitha Yaddanapudi’s laboratory helped us 
to examine CX3CR1+ Th1 and RORT+ Th17 cells in tumor-infiltrating T cells 
positive for CD4. As shown in Figure 3.6, the percentages of intratumoral 
CX3CR1+ Th1 and RORT+ Th17 cells CD4+ effector T cells were not 
significantly altered in mice vaccinated with ES-exo/GM-CSF and challenged 
with LLC cells compared with non-vaccinated control mice. 
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Figure 3.6. The levels of Th1 and Th17 effector cells in lung metastases 
are not affected by ES-exo/GM-CSF vaccination.  
Female C57BL/6 mice were vaccinated with 1 x PBS or ES-exo/GM-CSF 
twice (days 0 and 7). Seven days later, mice were injected with LLC cells 
through tail vein. Intratumoral CD4+ Th1 and CD4+ Th17 cells were 
examined 5 weeks following LLC inoculation. The pan-hematopoietic 
marker CD45 was evaluated to distinguish immune cells from cancer cells 
in lung metastases. (A) The presence of TBET+
 
Th1 in tumor-infiltrating 
CD3+CD4+ effector T cells was examined by flow cytometry. Numbers 
shown in plots are the percentage of each subpopulation. (B) Bar graphs 
showing average of percentages of TBET+
 
Th1 cells in tumor-infiltrating 
CD3+CD4+ cells acquired from control and ES-exo/GM-CSF-vaccinated 
mice with 4 mice in control group, 6 in ES-exo/GM-CSF group. Mean ± SD, 
n.s., not significant; ANOVA with Tukey’s multiple comparison test. (C) 
Intratumoral RORT+ Th17 cells in CD3+CD4+ effector T cells obtained from 
control and ES-exo/GM-CSF-vaccinated mice were evaluated. Numbers in 
the plots are the percentages of subpopulations. (D) The data shown in (C) 
are summarized. (n = 4 in control group, n = 6 in ES-exo/GM-CSF group; 
mean ± SD, n.s., not significant; ANOVA with Tukey’s multiple comparison 
test). 
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7. Vaccination with ES-exo/GM-CSF induces a tumor cell-specific 
cytokine response in tumor-infiltrating CD8+ T cells.  
Since cytolytic cytokines produced by tumor-infiltrating CD8+ T cells are known 
to contribute to the anti-tumor function of CD8+ T cells [143], With the help of 
Dr. Kavitha Yaddanapudi’s group, we investigated the capability of intratumoral 
CD8+ T cells from vaccinated mice to generate cytokines required for cytotoxic 
activity against tumors. Tumor-infiltrating immune cells were acquired from 
metastasized lung tumors in mice immunized with ES-exo/GM-CSF or the 
vehicle control. Following stimulation with LLC cell lysate, IFN- and TNF- 
levels in intratumoral CD8+ T cells were evaluated. As shown in Figure 3.7, a 
significantly higher percentage of IFN--producing CD8+ T cells were found in 
lung metastases in ES-exo/GM-CSF-vaccinated mice than their non-
vaccinated counterparts. However, the modest increase in IFN--producing 
CD8+ T cells promoted by ES-exo/GM-CSF vaccination was not significant.  
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Figure 3.7. Vaccination with ES-exo/GM-CSF promotes cytokine 
production from CD8+ T cells. 
Female C57BL/6 mice were immunized twice (days 0 and 7) with vehicle 
control (1 x PBS) or ES-exo/GM-CSF prior to tail vein injection with LLC. 5 
weeks after LLC challenge, lung tumors were resected, tumor-infiltrating 
cells were harvested and stimulated with LLC cell lysate for 6 hours. 
Intratumoral immune cells were identified by the pan-hematopoietic marker 
CD45 and intracellular expression of IFN-γ and TNF-α was examined by 
flow cytometry. (A) Dot plots showing IFN-γ expression in tumor-infiltrating 
CD3+CD8+ T cells obtained from control and ES-exo/GM-CSF-vaccinated 
mice. Numbers in plots represent the percentages of each subpopulation. 
(B) The data shown in (A) are summarized with 4 mice in control group, 6 
mice in ES-exo/GM-CSF group. Mean ± SD, **, p < 0.001; ANOVA with 
Tukey’s multiple comparison test. (C) The presence of TNF-α+
 
cells in tumor-
infiltrating CD45+CD3+CD8+ cells was examined by flow cytometry. 
Numbers indicated in plots are the percentage of each subpopulation. (D) 
Bar graphs showing average of percentages of TNF-α+
 
in intratumoral 
CD3+CD8+
 
T cells
 
derived from control and ES-exo/GM-CSF-vaccinated 
mice. (n = 4 per group; mean ± SD; **, n.s., not significant; ANOVA with 
Tukey’s multiple comparison test).  
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DISSCUSION 
The prevalence of pulmonary metastases from different primary tumors is 
relatively high due to the abundant bloodstream in the lung capillary bed [144]. 
Although there are several therapeutic options available for lung metastases, 
the overall outcome is still unsatisfactory. In this study, we investigated an 
experimental metastasis model where syngeneic LLC cells were administered 
directly into the bloodstream of wild-type C57BL/6 mice through tail vein 
injection, primarily resulting in pulmonary metastases [145]. Specifically, we 
examined the effects of a vaccine composed of exosomes from GM-CSF-
expressing ES-D3 cells on metastasized lung malignancy. Our data provide 
evidence that a vaccine derived from GM-CSF-expressing human ESCs could 
potentially be used to prevent the development of lung metastases in the future.  
In humans, metastasized lung malignancies are developed when cancer 
spreads to lung from where it originates. The metastasis mouse model in our 
study recapitulates the critical process of tumor cell extravasation from blood 
vessels in target organs, but it lacks the process of tumor cell metastasizing 
from primary tumor site and the generation of adhesion and traction forces 
required for cell migration [146]. Future research is warranted to investigate the 
efficacy of ES-exo/GM-CSF in tumor models more truthfully recapitulating the 
process of metastasis in lung cancer patients. 
Accumulating evidence indicate that stem-like cells, called cancer stem 
cells (CSCs) and more differentiated trophoblast-like cells coexist within lung 
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metastases. With self-renewal and differentiation capabilities similar to those of 
normal stem cells, CSCs are a likely source of cancer metastases. [147]. 
Furthermore, the presence of CSCs is a particular challenge in treating 
metastasized lung cancer because CSCs tend to be resistant to standard 
chemotherapy and radiotherapy. If lung CSCs could be recognized and 
eliminated by the immune system, the morbidity of cancer metastasis would 
likely decrease. Earlier studies suggest that the efficacy of ESC vaccination is 
associated with the immunity targeting CSCs [29]. In our study, vaccination with 
exosomes derived from ESCs induced immune responses against initiation and 
progression of lung metastases (Figure 3.1). It is conceivable that ES-exo/GM-
CSF vaccination triggers immune recognition and eradication of lung CSCs. 
Future studies are needed to address whether lung CSCs are the targets for 
this vaccination strategy against metastasized lung tumors.  
Emerging evidence has demonstrated that tumor-infiltrating lymphocytes 
(TILs) are deeply involved in metastasis of malignancy [133]. As ES-exo/GM-
CSF vaccination successfully blocked the outgrowth of metastasized lung 
tumors (Figure 3.1), we evaluated the comprehensive profile of intratumoral 
immune cells to elucidate the nature of immunity against lung metastases 
evoked by ES-exo/GM-CSF vaccination. In our research, we first observed a 
significant reduction in the presence of Tregs in lung metastases of 
vaccinated/tumor-challenged mice compared with non-vaccinated/tumor-
challenged control mice though Th17 cells which are relevant to suppress the 
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Tregs differentiation were unchanged after immunization (Figure 3.2; 3.6). This 
is consistent with the findings that increased Tregs population in metastasized 
malignancy often correlates with an immunosuppressive phenotype and poor 
patient prognosis [148]. Similarly, ES-exo-GM-CSF vaccination significantly 
decreased the abundance of MDSCs, particularly G-MDSC subset, in TILs 
(Figure 3.3). As a suppressor of T cell proliferation and activation, MDSCs 
expansion in TILs is an obstacle in tumor immunotherapy. Furthermore, it has 
been reported that the pulmonary G-MDSC infiltrates are dramatically 
increased as the metastases form in the lungs to suppress the anti-tumor 
immune response[149]. Therefore, the presence of two prominent suppressor 
populations that hamper anti-tumoral effector responses, Tregs and MDSCs, 
were suppressed by ES-exo/GM-CSF vaccination, which is correlated with the 
effectiveness of this vaccine.  
Tumor-associated macrophages are one of the major constituents that 
promote tumor progression by inhibiting tumor cell apoptosis and producing 
many pro-angiogenic factors [150]. Intratumoral macrophages have been 
linked to poor clinical outcome in lung cancer patients [137, 151]. In our study, 
percentage of F4/80+ macrophages in TILs was significantly decreased by 
immunization of ES-exo/GM-CSF compared with the control group (Figure 
3.4B). As one subtype of macrophages, CX3CR1+ macrophages are involved 
in lung cancer growth and metastasis [139]. However, we failed to observe any 
significant difference in CX3CR1+ populations between the mice in the 
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vaccinated group and their counterparts in the control group (Figure 3.4D).  
Like many other intratumoral immune cells, macrophages infiltrated into 
tumors also display multifaceted activities to regulate tumor immunity, rather 
than simply stimulating or hindering tumorigenesis and metastasis [152]. There 
are two distinct subtypes of macrophages existing in tumor infiltrates: pro-
inflammatory, anti-tumor M1 class and anti-inflammatory, pro-tumor M2 class. 
In the majority of solid tumors, M2 macrophages are considered as the 
dominant subtype, conferring an immunosuppressive microenvironment to 
support malignancy progression. However, the composition of tumor-infiltrating 
macrophages is heterogeneous and complicated, which is determined by the 
cancer type, malignancy development stage, tumor size, as well as location of 
cancer cells in malignant tissues [152]. Future studies will reveal the effects of 
ES-exo-GM-CSF vaccination on the identity and heterogeneity of macrophages 
in lung tumor metastasis. 
It has been demonstrated that Th1 and Th17 subsets of CD4+ T cells are 
involved in lung malignancy and metastasis [141, 142]. Th1 cells increase cell-
mediated immune responses by producing effector cytokines, including IFN-. 
Th1 immunity contributes to activation of CD8+ T cells and IFN- expression in 
CD4+ T cells [153]. As a subset of pro-inflammatory T helper cells, Th17 cells 
are defined by their production of IL-17. The signals from Th17 cells are related 
to inhibition of Treg differentiation [154]. In our study, there was no significant 
change in the presence of Th1 and Th17 cells in pulmonary tumor infiltrates 
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between mice immunized with ES-exo-GM-CSF and their non-vaccinated 
counterparts (Figure 3.6), suggesting that this vaccination strategy elicits 
immunity through mechanisms independent of Th1 and Th17. 
CD8+ cytotoxic T cells are known to induce anti-tumor immunity by 
producing cytolytic cytokines, such as IFN- and TNF- [155]. However, 
cytokines released from tumor-infiltrating CD8+ T cells are one of the crucial 
contributing factors in immune response against cancer cells [155]. ES-
exo/GM-CSF vaccination significantly boosted the frequency of IFN--
producing CD8+ cytotoxic T cells in lung metastases (Figure 3.7), which is 
consistent with the data acquired from subcutaneously injected lung tumors 
(Figure 2.11). However, the levels of TNF--producing CD8+ cytotoxic T cells in 
metastasized pulmonary malignancies were unaffected by ES-exo/GM-CSF 
vaccination. In contrast, the levels of TNF--generating CD8+ cytotoxic T cells 
in subcutaneously implanted lung tumors were markedly increased by ES-
exo/GM-CSF vaccination, suggesting that different tumor microenvironments 
might determine the production of cytokines by CD8+ cytotoxic T cells.  
In our studies, when tumor-infiltrating immune cells were acquired for 
immunoanalysis, tumor metastases in the lungs of mice vaccinated with ES-
exo-GM-CSF were much smaller than those of non-vaccinated mice (Figure 
3.1). The observed difference in intratumoral lymphocyte profiles between 
vaccinated group and control group could be partially attributed to various 
stages of lung metastases. More experiments are warranted to examine tumor-
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infiltrating immune cells from lung metastases at similar stages in the future. 
In summary, the protection against metastasized lung cancer afforded by 
ES-exo/GM-CSF vaccination involves a number of immune response pathways. 
Future studies will focus on elucidating how this vaccination strategy not only 
promotes the effector function of the immune system but also suppresses 
various immune evasion mechanisms conferred by developing lung 
metastases, which is attributed to the robust efficacy against metastasized 
pulmonary malignancies. 
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CHAPTER IV 
THE PLURIPOTENCY OF EMBRYONIC STEM CELLS IS ESSENTIAL FOR 
CANCER-PREVENTION EFFICACY OF EMBRYONIC STEM CELL-BASED 
VACCINE 
 
INTRODUCTION  
The association between embryonic materials and tumors has initiated many 
research activities on exploring the therapeutic potential of embryonic stem 
cells (ESCs) against cancer [26, 29]. In the 1960s, Triolo proposed a theory that 
cancer originates from ESCs [84], indicating that cancer cells possess similar 
characteristics as ESCs. It is well known that ESCs and tumor cells share some 
antigens. Since 1960s, the antigen overlap between embryonic tissues and 
neoplastic cells, such as carcinoembryonic antigen (CEA), prostate-specific 
antigen (PSA), and cancer/testis antigen (CTA), has been extensively studied, 
[18]. However, the full extent to which embryonic/cancer tissues overlap in 
antigens remains unknown. Thus, understanding this overlap remains an area 
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of ongoing research. It has been demonstrated that embryonic materials 
possess immune regulatory activity to prevent cancers as a vaccination 
strategy [26]. Exploiting the antigenic similarity between malignant cells and 
ESCs, a recent study reports the development of an anti-lung cancer vaccine 
based on allogeneic murine ESCs along with allogeneic murine fibroblasts 
expressing granulocyte-macrophage colony stimulating factor (GM-CSF) as an 
immunostimulatory adjuvant [26]. Another study provides support for this 
strategy by demonstrating that irradiated, induced pluripotent stem cells (iPSCs) 
function as a prophylactic vaccine against transplanted lung tumors [30]. 
Nevertheless, further research is needed to completely elucidate how the 
similarity between cancer cells and ESCs contributes to the immunity of ESCs 
against cancer. 
The pluripotency of ESCs is one of the most specialized properties shared 
with cancer stem cells [156]. Both tumors and stem cells are capable of self-
renewal and phenotypic plasticity[156]. The prognosis of human malignancies 
often depends on the differentiation status of the tumor type with the worst 
prognosis usually induced by poorly differentiated tumors. A panel of genes 
identified in different histologically poorly differentiated tumors are normally 
enriched in ES cells [85]. Their results indicate that genes encoding specific 
transcriptional regulators in ESCs are often overexpressed in poorly 
differentiated tumors. This suggests that the preventative effect of ESCs against 
cancer is likely attributed to their pluripotency. 
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It appears that the mechanisms involved in the prophylactic efficacy of 
vaccines derived from diverse early stage embryonic cells vary to a certain 
degree. When immunized with a vaccine consisting of murine ESCs along with 
GM-CSF, mice display robust tumor-reactive primary and memory CD8+ T 
effector responses against lung malignancy [29]. In contrast, anti-cancer 
immunity of an iPSC-based vaccine is associated with reduction of a subset of 
pro-inflammatory T helper cells Th17 and increased CD11b+GR1hi myeloid-
derived suppressor cells [30].  
Immunization with antibodies specific for tumor‐associated antigens has 
been reported to trigger an immunological response against tumor cells through 
antibody-dependent cellular cytotoxicity (ADCC), a cell-mediated immune 
defense mechanism [157-159]. In this process, membrane-surface antigens of 
cancer cells are recognized by specific antibodies, leading to the interaction 
between antibodies and effector immune cells as well as subsequent the lysis 
of tumor cells. Since ADCC relies on a preceding antibody response to be 
effective, it is part of the adaptive immune response. Although natural killer (NK) 
cells are known to be the typically effector cells to eliminate neoplastic cells 
during ADCC, macrophages, neutrophils and eosinophils are also capable of 
mediating ADCC against cancer [160-163]. Currently, the cellular populations 
responsible for ADCC in the context of ESC-derived tumor vaccines is unknown. 
Therefore, further research is needed to determine the involvement of ADCC in 
the prophylactic efficacy of ESC-derived anti-tumor vaccines. 
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In this study, we explored the importance of pluripotency of ESCs in their 
prophylactic efficacy against lung cancer. We also investigated the antigens 
specific for the antibodies generated by ESC-based vaccines.   
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MATERIALS AND METHODS 
1. Cell lines 
Murine embryonic stem cell line ES-D3 (CRL-11632) and murine Lewis lung 
carcinoma (CRL-1642) were acquired from ATCC (Manassas, VA). Murine 
fibroblast cell line STO (ATCC # CRL-1503) infected with a replication-defective 
retrovirus expressing murine granulocyte-macrophage colony-stimulating 
factor (GM-CSF) cDNA was acquired from Dr. Glenn Dranoff (Novartis Institutes 
for Biomedical Research; Boston, MA). ES-D3 cells and Lewis lung carcinoma 
(LLC) were cultured as described in Chapter 2. STO cells were grown and 
maintained in Dulbecco's modified eagle's medium (SH30243.LS; GE Life 
Sciences; Pittsburgh, PA) supplemented with 10% fetal bovine serum (900-108; 
Gemini; Broderick, CA), 100 units/ml penicillin (sc45000-652; Mediatech; 
Manassas, VA) and 100 µg/ml streptomycin (sc45000-652; Mediatech). GM-
CSF produced by STO cells was evaluated by measuring GM-CSF 
concentration in the culture medium with a murine GM-CSF ELISA kit 
(88733422; Thermo Fisher; Waltham, MA) following manufacturer’s protocol. 
All of the cells were cultured in a 5% CO2 humidified incubator at 37oC. 
2. Mice 
Wild-type male and female C57BL/6 mice (8 weeks of age) were acquired from 
Jackson Laboratory (Bar Harbor, ME). Mice were maintained at the University 
of Louisville Research Resources Facilities (RRF). The facility is accredited by 
the American Association for the Accreditation of Laboratory Animal Care 
(AAALC), and adheres to the "Guide for the Care and Use of Laboratory 
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Animals" (Institute of Laboratory Animal Resources, National Research Council, 
National Academy Press, 1996). The Institutional Animal Care and Use 
Committee (IACUC) at the University of Louisville has approved the mouse 
study (protocol number: 18301). 
3. Differentiation of murine ESCs  
Murine ESCs were differentiated into neuronal cells following a published 
protocol [164]. Briefly, ES-D3 cells were seeded onto a standard 10-cm petri 
dish in standard ESC media lacking leukemia inhibitory factor (LIF) and β-
mercaptoethanol. Two days later, the media was replaced with fresh medium, 
and the cells were cultured for 2 additional days. Next, media was replaced with 
fresh media containing 0.5 M retinoic acid (R2625; Sigma-Aldrich; St. Louis, 
MO) and the cells were cultured for 2 days. Finally, the cells were cultured in 
fresh retinoic acid-containing media for another 2 days. The morphology of 
differentiated cells was examined using an EVOS cell imaging system (Thermo 
Fisher). The efficacy of differentiation was evaluated by examining the 
pluripotency of differentiated cells with measurement of SSEA-1, SSEA-4 and 
Oct-3/4 expression levels by flow cytometry as described in Chapter 2.  
4. Anchorage-independent cell culturing 
After heating in a 42°C water bath for 30 minutes, 3.5% soft agar solution was 
diluted to 0.7% with fresh ES-D3 cell culture medium. To form the agar base, 3 
ml of 0.7% agar solution was plated in each well of a 6-well tissue culture plate. 
The agar in the plates was then solidified at 4°C for 30 minutes. Parental ES-
D3 cells, differentiated ES-D3 cells, and Lewis lung carcinoma (LLC) cells (3 ᵡ 
103 or 7.5 ᵡ 103) were transferred on top of agar base in each well in a final 
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volume of 3 ml 0.7% agar solution. Each cell line and seeding density was 
plated in duplicate. The plates were placed at 4°C for 5 minutes before being 
transferred to a 5% CO2 humidified incubator at 37°C for 8 day-culture. The 
plates were then stained with 1 mg/ml iodonitrotetrazolium chloride (I10406; 
Sigma-Aldrich) overnight. The images were acquired using an EVOS cell 
imaging system and the numbers of cell colonies were determined using the 
software ImageJ (National Institutes of Health; Bethesda, MD).    
5. Vaccination against tumor challenge 
Parental or differentiated ESCs and STO cells overexpressing GM-CSF were 
disassociated from tissue culture plates with 0.05% trypsin/EDTA (25-052-CI; 
Corning; Corning, NY). Collected cells were washed twice with sterile 1 x PBS 
and suspended in 1 x PBS at a concentration of 10 ᵡ 106/ml. Parental or 
differentiated ESCs (1 ᵡ 106) along with GM-CSF-expressing STO cells (1 ᵡ 106) 
were injected subcutaneously (s.c.) in the right flank of 8-week old male or 
female C57BL/6 mice. Primary vaccination was carried out on day 0, and a 
boost vaccination was administered on day 7. Next, 7 days after the second 
vaccination, vaccinated mice were subcutaneously administered with LLC cells 
(0.15 × 106) on the left flank. Side effects of tumor development in mice were 
monitored daily, and the resultant tumors were evaluated using dull-edged 
Vernier calipers. Tumor growth was monitored by measuring tumor width (W) 
and length (L) in mm using calipers every other day and tumor volumes (V) in 
mm3 were calculated by the following formula: V = (W * W * L) / 2. Mice were 
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euthanized when tumors exceeded 5% of body weight. The remaining mice 
were tumor-free with no overt signs of distress. On day 72, tumor-free mice 
were challenged with LLC cells (0.15 × 106) for second time by subcutaneous 
injection on the left flank. Tumor growth was monitored daily. 
6. Proteomics analysis of exosome samples 
Exosomes isolated from ES-D3 cells were extracted with lysis buffer containing 
50 mM Tris (pH7.4), 150 mM NaCl, 1% NP-40, and 0.05% SDS and stored at 
4°C. Exosome lysate was analyzed at the Genome Center, University of 
California at Davis. Following the standard procedure of protein digestion by 
Trypsin/Lys-C (V5071; Promega; Madison, WI), exosomes were desalted by 
C18 Microspin columns (SEMSS18V; Nest Group; Southborough, MA) and 
lyophilized by vacuum centrifugation. Liquid chromatography (LC) separation 
was carried out with an Easy-nLC 1000 LC system (Thermo Fisher Scientific). 
Then digested peptides were reconstituted in 2% acetonitrile/0.1% 
trifluoroacetic acid. The samples (3 µg) were loaded onto a 100 micron × 25 
mm Magic C18 100Å 5U reverse phase trap where they were desalted online 
before being separated on a 75 micron × 150 mm Magic C18 200Å 3U reverse 
phase column. Peptides were eluted with a gradient of 0.1% formic acid (A) and 
100% acetonitrile (B), which was run with 5% to 35% B (45 minutes), 35% to 
80% B (8 minutes), 80% B (1 minute), 80% to 5% B (1 minute), and 5% B (10 
minutes). The collection of mass spectra (MS) was carried out with a mass 
spectrometer (Orbitrap Q Exactive Plus; Thermo Fisher Scientific) in a data-
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dependent mode with MS precursor scan followed by 15 MS/MS scans. A 
dynamic exclusion of 15 s was used. All MS/MS samples were analyzed using 
X! Tandem (CYCLONE; 2013.02.01.1) to search the uniprot mouse proteome 
plus an equal number of reverse decoy sequences (142010 entries). MS/MS-
based peptide and protein identifications were validated with the software 
Scaffold (Scaffold_4.8.2; Proteome Software; Portland, OR). Peptide 
identifications were accepted if they could be established at greater than 98.0% 
probability by the Scaffold Local FDR algorithm. Protein identifications were 
accepted if they could be established at greater than 5.0% probability to achieve 
an FDR less than 5.0% and contained at least one identified peptide. 
7. Antigen capture experiments for mice immunized with exosomes. 
Male C57BL/6 mice (8 weeks of age, 2 mice/group) were immunized twice (day 
0 and day 7) with vehicle only (1x PBS) or 225 µg of exosomes isolated from 
ES-D3 cells stably-expressing GM-CSF by subcutaneous injection. Seven days 
following the second vaccination, whole blood was collected by cardiac 
puncture immediately after CO2 asphyxiation. Whole blood was transferred to 
serum separator tubes (365967; Beckon Dickinson; Franklin Lakes, NJ) and 
serum was collected. Protein A agarose beads (200 µl; 9863S; Cell Signaling; 
Danvers, MA) were resuspended with 1 ml binding buffer containing 50 mM Tris 
(pH7.5) and 150 mM NaCl and centrifuged at 390 x g for 30 seconds. Binding 
buffer was removed and wash was repeated twice. The mouse serum collected 
from 2 mice was combined (200 µl, 100 µl from each mouse) and added to the 
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tubes containing the beads. The mixture was incubated on a rotator for 3 hours 
at room temperature. 
Exosomes isolated from ES-D3 cells expressing GM-CSF (9 mg) were 
resuspended in 1.2 ml 2 X lysis buffer containing 100 mM Tris (pH7.5), 300 mM 
NaCl, 2% NP-40, 0.05 % SDS, protease inhibitor (P8349; Sigma-Aldrich) and 
phosphatase inhibitor (04 906 845 001; Roche Diagnostics; Indianapolis, IN). 
The lysate of exosomes was first sonicated with 10% amplitude for 5 seconds 
using a Sonic Dismembrator (Branson Digital Sonifier, Thermo Fisher).  The 
exosomal lysate of was then passed through an insulin syringe 10 times and 
centrifuged at 13,000 x g for 10 minutes at 4°C. The supernatant was taken out 
as exosomal extract for the antigen binding experiment. The serum-bead 
mixtures were centrifuged at 390 x g for 30 seconds at 4°C. The beads were 
washed for 3 times with 500 μl of lysis buffer by rotating for 10 minutes at 4°C. 
The exosomal extract (1 ml) was added to each tube containing the beads, and 
the tubes were rotated at 4°C overnight. Then the extract-bead mixtures were 
centrifuged at 390 x g for 30 seconds at 4°C. The beads were washed 5 times 
with 1 ml of binding buffer by rotating for 10 minutes at 4°C. Abundance of 
proteins bound to the beads was evaluated by proteomic analysis at the 
Genome Center, University of California at Davis.  
8. Antigen capture experiments for mice immunized with ESCs. 
Vehicle only (1 x PBS) or ES-D3 cells (1 x 106) combined with STO-fibroblasts 
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expressing GM-CSF (1 x 106) were subcutaneously injected at right flank into 
eight-week old male C57BL/6 mice (2 mice/group) twice with one week apart. 
One week following the second immunization, serum was collected as 
described previously. Collected serum was incubated with protein A agarose 
beads in the same fashion as the serum acquired from mice immunized with 
exosomes as described above. 
ES-D3 cells were collected (30 ᵡ 106 cells/each group) by trypsinization. 
Cell pellets were resuspended in 5 ml lysis buffer and sonicated at 20% 
amplitude (Branson Digital Sonifier) twice for 5 seconds each time with at least 
one minute-rest on ice between each 5-second pulse. Then the cell lysate was 
pushed through an insulin syringe 10 times and centrifuged in a microcentrifuge 
at 13,000 x g for 10 minutes at 4°C. The supernatant was taken out as whole 
cell extract for the antigen binding experiment. Whole cell extract was then 
added to protein A agarose beads pre-incubated with the serum as described 
above for the serum from exosome-vaccinated mice. Samples were then 
examined by proteomics analysis. 
9. Proteomics analysis of protein samples bound to beads  
Protein samples bound to protein A agarose beads were washed four times with 
200 ml of 50 mM ammonium bicarbonate (AMBIC; A6141; Sigma-Aldrich) with 
a 20-minute shake at 4°C between each wash. About 2.5 µg of Trypsin/Lys-C 
(V5071; Promega) was added to the beads and AMBIC mixture and the 
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samples were digested overnight at 800 x rpm shake speed. Following 
digestion, the supernatant was transferred to a microfuge tube and the beads 
were washed once with 50 mM AMBIC. After a 20-minute gentle shake, the 
wash was transferred and combined with the initial supernatant. The peptide 
extracts were reduced in volume by vacuum centrifugation and a small portion 
of the extract was used for fluorometric peptide quantification (23290; Thermo 
Fisher Scientific). One microgram of sample based on the fluorometric peptide 
assay was loaded for each LC-MS analysis. 
Digested peptides were analyzed by LC-MS/MS on a Thermo Scientific Q 
Exactive Orbitrap Mass spectrometer in conjunction Proxeon Easy-nLC II 
HPLC (Thermo Fisher Scientific) and Proxeon nanospray source. The digested 
peptides were loaded a 100 micron x 25 mm Magic C18 100Å 5U reverse phase 
trap where they were desalted online before being separated using a 75 micron 
x 150 mm Magic C18 200Å 3U reverse phase column. Peptides were eluted 
using a 60-minute gradient with a flow rate of 300 nl/min. An MS survey scan 
was obtained for the m/z range 300-1600, MS/MS spectra were acquired using 
a top 15 method, where the top 15 ions in the MS spectra were subjected to 
HCD (High Energy Collisional Dissociation). An isolation mass window of 2.0 
m/z was for the precursor ion selection, and normalized collision energy of 27% 
was used for fragmentation. A 15-second duration was used for the dynamic 
exclusion. 
Tandem mass spectra were extracted and charge state was deconvoluted 
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by Proteome Discoverer (Thermo Fisher Scientific). MS/MS samples were 
analyzed using X! Tandem (The GPM, thegpm.org; version TORNADO 
(2013.02.01.1)). X! Tandem was set up to search (20180405 Uniprot Mouse) 
database (108924 entries), the cRAP database of common laboratory 
contaminants (www.thegpm.org/crap; 114 entries) plus an equal number of 
reverse protein sequences assuming the digestion enzyme trypsin. X! Tandem 
was searched with a fragment ion mass tolerance of 20 PPM and a parent ion 
tolerance of 20 PPM. Deamidation of asparagine and glutamine, oxidation of 
methionine and tryptophan, sulphone of methionine, tryptophan oxidation to 
formylkynurenin of tryptophan and acetylation of the n-terminus were specified 
in X! Tandem as variable modifications. 
Scaffold (version 4.4.1, Proteome Software) was used to validate MS/MS- 
based peptide and protein identifications. Peptide identifications were accepted 
if they could be established at greater than 85.0% probability by the Scaffold 
Local FDR algorithm. Protein identifications were accepted if they could be 
established at greater than 80.0% probability to achieve an FDR less than 5.0% 
and contained at least 1 identified peptide. Protein probabilities were assigned 
by the Protein Prophet algorithm (reference). Proteins that contained similar 
peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony. Proteins sharing significant 
peptide evidence were grouped into clusters. 
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10. Statistical analysis 
All of the experiments were performed in replicates. The statistical analysis was 
carried out by the student t-test and the analysis of variance (ANOVA). A P value 
< 0.05 was considered significant.  
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RESULTS 
1. The pluripotency of murine embryonic stem cells (ESCs) is reduced 
during differentiation 
ESCs and lung cancer cells express common protein markers and share 
several genotypic and phenotypic traits [11, 18, 165]. Among them, pluripotency 
is one of the most specialized properties shared between ESCs and a subset 
of lung tumor cells, cancer stem cells (CSCs). We reasoned that the anti-lung 
tumor immunity generated by ESC-based vaccine, either as intact cells or as 
secreted exosomes, is likely attributed to shared carcinoembryonic antigens 
whose expression is reduced or eliminated during differentiation. A published 
approach was employed to differentiate murine ESC line ES-D3, in which 
deprivation of extrinsic self-renewal signals from leukemia inhibitory factor (LIF) 
coupled with the addition of retinoic acid drove undifferentiated cells to become 
neuronal cells [164, 166]. Morphological characterization of parental and 
differentiated ES-D3 cells was carried out using microscopy (Figure 4.1A). 
Undifferentiated parental ES-D3 cells had morphology of typical ESCs with 
rounded cell shape and smooth cytoplasmic membrane, and they generated 
close cytoplasmic membrane contact with each other to form colonies [167]. In 
contrast, differentiated ES-D3 cells displayed different morphology with 
dendrite-like protrusions, which is consistent with the morphological 
characteristics of neuronal cells [168].  
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A number of molecular markers have been reported to be indicative of the 
pluripotency of murine ESCs, among which SSEA-1, SSEA-4, and Oct-3/4 
expression are commonly studied to examine the pluripotency status [169]. 
Generally, pluripotent murine ESCs exhibit elevated SSEA-1 and Oct-3/4 
reactivity, but low expression of SSEA-4 [170]. Therefore, the pluripotency of 
differentiated ES-D3 cells was evaluated by measuring SSEA-1, SSEA-4 and 
Oct-3/4 expression levels via flow cytometry as described earlier (Figure 2.3). 
Loss of pluripotency of differentiated ES-D3 cells was indicated by decreased 
SSEA-1 and Oct-3/4 expression and increased SSEA-4 expression compared 
with parental ES-D3 cells (Figure 4.1B). Overall, differentiated ES-D3 cells are 
distinct from their undifferentiated counterparts at both morphological and 
molecular levels. 
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Figure 4.1. Differentiated ES-D3 cells are characterized.  
Murine embryonic stem cell line ES-D3 cells were cultured in the absence of 
LIF and β-mercaptoethanol for 4 days. Then ES-D3 cells were cultured in 
the presence of 0.5 mM retinoic acid for 4 days. (A) Representative images 
of parental and differentiated ES-D3 cells. Scale bar, 10 µM. (B) Flow 
cytometry analysis of the expression of pluripotency and differentiation 
markers (SSEA-1, Oct3/4 and SSEA-4) in parental and differentiated ES-D3 
cells. 
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2. The pluripotency of ESCs is important for their anchorage-independent 
growth potential 
A hallmark of tumorigenesis is the proliferation of neoplastic cells without a solid 
surface, aka anchorage-independent growth, which correlates with tumorigenic 
and metastatic potential in vivo [171]. The soft agar colony formation assay is 
a well-accepted method to evaluate anchorage-independent growth [172]. Due 
to anoikis, a particular type of apoptosis, no colonies are formed when normal 
cells are plated in an anchorage-independent culture model [173]. Although 
ESCs and malignant cells share some genotypic and phenotypic traits, it was 
unclear whether ESCs possess anchorage-independent growth potential, as 
tumor cells do. Equal numbers of parental ES-D3 cells and Lewis lung 
carcinoma (LLC), an aggressive non-small cell lung cancer cell line, were 
seeded in soft agar. As shown in Figure 4.2, LLC cells and parental ES-D3 cells 
showed similar anchorage-independent growth capacity. To our knowledge, this 
is the first study demonstrating that the anchorage-independent growth 
potential of undifferentiated ESCs is the same as that of lung tumor cells. To 
further explore the involvement of pluripotency of ESCs in anchorage-
independent cell growth, we examined the ability to form colonies in soft agar 
of differentiated ES-D3 cells, which was reduced to extremely low levels 
compared with those of undifferentiated ES-D3 and LLC cells. These results 
indicate that pluripotency of ESCs is critical for their ability to evade anoikis and 
grow independent of a solid surface. 
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Figure 4.2. Differentiation inhibits anchorage-independent proliferation 
of ES-D3 cells. 
The anchorage-independent growth capability of differentiated ES-D3 cells 
and their parental counterparts was examined by a soft agar colony 
formation assay. (A) The indicated number of LLC, parental ES-D3 cells and 
differentiated ESD3 cells were cultured in soft agar for 8 days. 
Representative images of the plates are shown. (B) The colonies of LLC, 
parental ES-D3 and differentiated ES-D3 on the soft agar plates shown in 
(A) were counted. The data are presented as means ± standard deviations 
of three independent experiments. Student's unpaired t test. Asterisks (**), 
indicate p < 0.001. “ns”, no significance.  
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3. Differentiation decreases the efficacy of ESC vaccine on lung tumor 
development   
Once the reduction in pluripotency of ES-D3 cells by differentiation was 
confirmed, the role of pluripotency in anti-tumor efficacy of ES-D3 cells was 
evaluated. To ensure rigor and reproducibility, animal studies were designed to 
include appropriate control and treatment groups with both sexes. To achieve 
power and statistical significance, there were 8 animals in each experimental 
group. Subcutaneous (s.c) injection of vaccines was carried out to induce 
immunization as described earlier [29]. Three groups of C57BL/6 mice were 
immunized (aged 8 weeks, 8 per sex per group): vehicle control (1 x PBS), 
undifferentiated ES-D3 and STO fibroblasts expressing GM-CSF (UNDIFF + 
STO ) or their differentiated counterparts along with GM-CSF-expressing STO 
cells (DIFF + STO ). Mice were immunized twice (day 0 and day 7) followed by 
a challenge with subcutaneous injection of highly aggressive LLC cells (0.15 × 
106) at day 14. The kinetics of tumor growth were closely monitored by 
measuring both the longitudinal and transverse diameters of tumors using 
digital calipers every 2 days as described above. As depicted by Kaplan-Meier 
survival curves shown in Figure 4.3, all non-vaccinated control animals died 
within 28 days of tumor cell challenge, whereas 56% of mice vaccinated with 
undifferentiated ES-D3 cells survived beyond 38 days. Importantly, only 31% of 
animals immunized with differentiated ES-D3 survived for the 28-day period, 
indicating that differentiation decreases the cancer prevention efficacy of ESCs. 
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Furthermore, the results obtained from male mice are very comparable with 
those from female mice. In the case of tumor development, all control mice 
developed tumors 14 days after LLC cell administration (Figure 4.4). In contrast, 
56% (n=16) of mice vaccinated with undifferentiated ES-D3 cells were 
protected from tumor outgrowth by day 32 post-challenge. Moreover, 
differentiated ES-D3 cells vaccination decreased the efficacy of the 
immunization against lung cancer by 31% compared to undifferentiated ES-D3 
cells. Tumor growth patterns were similar between both sexes.  
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Figure 4.3. Differentiation decreases the efficacy of ES-D3 cells against 
lung cancer.  
(A) The scheme of immunization is shown. Male and female C57BL/6 mice 
were immunized twice with 1 x PBS (vehicle control), parental ES-D3/STO 
expressing GM-CSF (UNDIFF + STO) or differentiated ES-D3/STO-
expressing GM-CSF (DIFF + STO) prior to s.c. challenge with LLC cells (0.15 
× 106). Tumor growth was monitored daily in all mice until they were 
euthanized due to tumors exceeding 5% of body weight. (B) Kaplan-Meier 
survival curve demonstrates the probability of tumor-free survival in male 
mice (n=8). (C) Kaplan-Meier survival curve compares the survival of female 
mice in different vaccination groups (n=8). (D) The data shown in (B) and (C) 
are combined (16 mice/group). 
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Figure 4.4. Differentiation of ES-D3 cells inhibits their ability to prevent 
lung cancer.  
C57BL/6 mice were vaccinated twice (days 0 and 7) with 1 x PBS (vehicle 
control), parental ES-D3/STO expressing GM-CSF (UNDIFF + STO) or 
differentiated ES-D3/STO expressing GM-CSF (DIFF + STO) followed by 
s.c. injection of 0.15 × 106 LLC cells on day 14. Tumor growth was examined 
daily. (A) The percentage of tumor-free male mice (8 mice/group) are shown. 
(B) The data of tumor occurrence in female mice (8 mice /group) are 
presented (C) Tumor development in both male and female mice is 
evaluated (16 mice/group, 8 mice/gender). 
A 
B 
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More importantly, the growth of LLC tumors that developed in mice 
vaccinated with undifferentiated ES-D3 cells was slower compared with those 
of non-vaccinated control mice and mice immunized by differentiated ES-D3 
cells (Figure 4.5). These results lend more credence to the notion that the 
differentiation of ESCs decreases their anti-tumor efficacy in mice.  
 
 
 
 
 
 
 
Figure 4.5. Differentiation reduces anti-cancer activities of ES-D3 cells. 
C57BL/6 mice were injected twice (days 0 and 7) with 1 x PBS (vehicle 
control), parental ES-D3/STO expressing GM-CSF (UNDIFF + STO) or 
differentiated ES-D3/STO expressing GM-CSF (DIFF + STO). On day 14, 
LLC cells (0.15 × 106) was inoculated into mice by s.c. injection. Tumor 
growth was determined by dull-edged Vernier calipers every two days. 
Tumor volumes are presented as means ± standard deviations. The data 
represent male mice (A), female mice (B) and both genders (C). 
A B 
C 
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To evaluate the involvement of ESC pluripotency in the generation of long-
term immunity against lung cancer, we tested the anti-tumor responses using 
mice that had been vaccinated and protected successfully for 58 days. The 
previously LLC-challenged tumor-free mice were injected with LLC cells for a 
second time (Figure 4.6A). Notably, 2 tumor-free mice vaccinated with 
differentiated ES-D3 cells developed tumors 8 days after the second LLC 
challenge, whereas only 20% of mice (n=8) in the UNDIFF+STO vaccination 
group developed tumors following LLC cell re-inoculation (Figure 4.6B). This 
provides evidence that the pluripotency of ESCs is essential for their long-term 
anti-tumor activities.  
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Figure 4.6. Differentiation decreases long-term cancer prevention 
potential of ES-D3 cells  
(A) The scheme of vaccination is shown. tumor-free C57BL/6 mice were 
immunized with parental ES-D3/STO expressing GM-CSF (UNDIFF + STO) 
or differentiated ES-D3/STO expressing GM-CSF (DIFF + STO) twice (days 
0 and 7), followed by injection inoculation of 0.15 × 106 LLC cells on day 14. 
Tumor-free mice were challenged again with LLC cells (0.15 × 106) again at 
day 72. Tumor development was monitored daily until sacrifice due to tumor 
sizes reaching the limit (5% of body weight). (B) 28 days after second LLC 
challenge, the percentages of tumor-free mice in each group were 
determined. 
A 
B 
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4. ES-D3 cells and lung tumor cells exhibit antigenic similarity as revealed 
by antigen capture experiments 
There is abundant evidence that malignant cells and ESCs share 
carcinoembryonic antigens, which are not expressed in normal adult tissues 
[18]. Those antigens play an important role in cancer vaccination, as they 
enable the immune system to distinguish tumor cells from nontumor cells, 
resulting in potential cancer rejection. Since exosomes derived from murine 
ESCs engineered to produce GM-CSF significantly slowed or blocked the 
outgrowth of implanted LLC (Figure 2.6), we first examined the presence of 
proteins in exosomes derived from ES-D3. As shown in Table 4.1, tumor 
antigens identified in a variety of tumor types, such as alpha fetoprotein (AFP), 
lactate dehydrogenase (LDH) and fibrinogen, were also present in exosomes 
derived from ES-D3 cells [174-180], which is in agreement with the notion that 
embryos and tumors share a group of similar antigens [19, 97, 98].  
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Table 4.1 Exosomes derived from ES-D3 cells contains various tumor 
antigens.  
Tumor antigens presented in exosomes isolated from ES-D3 cells were 
identified by a proteomics approach. 
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Since the antigens responsible for prophylactic efficacy of intact ES-D3 
cells or exosomes isolated from ES-D3 cells have not been identified yet, we 
carried out a series of experiments to thoroughly explore this issue. It is possible 
that the antibodies generated by ESC-based vaccine directly recognize 
neoplastic cells and initiate antibody-dependent cellular cytotoxicity (ADCC). To 
gain a comprehensive understanding of the antigenicity of ESC vaccine, a novel 
immunoproteomic strategy was employed (Figure 4.7). This approach has the 
potential to reveal the complete repertoire of potentially immunogenic antigens 
in the serum of immunized mice. This combined affinity chromatography 
shotgun immunoproteomic approach starts with capture of antibodies in the 
serum by an IgG affinity column [181]. Specifically, mice (C57BL/6) were 
immunized with either a cell-based vaccine (ES-D3 cells + STO expressing GM-
CSF) or an exosome-based vaccine (exosome from GM-CSF-expressing ES-
D3) as described in “Materials and Methods”. After the binding of antibodies to 
protein A beads, antigen-containing ESC lysates or exosomal lysates were 
loaded to the respective mixture of protein A beads and antibodies from serum. 
Bound antigens were identified by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) analysis.  
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Figure 4.7. An immunoproteomics strategy to identify the antigens 
specific for the antibodies generated by vaccines derived from ESCs. 
The schematic description of a combined affinity chromatography shotgun 
immunoproteomics approach. C57BL/6 mice were immunized with a vaccine 
composed of ES-D3 cells and STO fibroblasts expressing GM-CSF) or a 
vaccine composed of exosomes from GM-CSF expressing ES-D3 cells. 
Lysates containing antigens of cell- or exosomes-based vaccine were loaded 
to Protein A agarose beads bound with serum antibodies. LC-MS/MS studies 
were conducted to identify the antigens bound to the beads 
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For the serum acquired from the mice vaccinated with the cell-based 
vaccine, the presence of 136 immunoglobin-unrelated proteins in the serum of 
immunized mice is higher than their control counterparts (Figure 4.8A). Among 
them, 16 identified proteins are members of keratin family and 11 keratin types 
are cancer related (Table 4.2). Although keratin members are fibrous proteins 
that form the structural framework of epithelial cells, some of them are 
commonly used as diagnostic markers for cancers with various epithelial origins, 
due to their distinctive expression patterns [182]. Importantly, several keratin 
proteins associated with lung malignancy, keratin 7, 8, 16, 17, and 19, were 
identified in the serum of mice vaccinated with intact ES-D3 cells (Table 4.3). 
Similarly, the exosome-based vaccine generated antibodies recognizing 
132 non-immunoglobin proteins compared with the vehicle control (Figure 
4.8B). Consistent with the results acquired from the cell-based vaccine, a large 
portion of identified antigens (25 out 132) are keratin members. 10 of which are 
cancer related (Table 4.2). Furthermore, lung tumor-associated keratin 
members 8, 14, 16, and 17 were also enriched in the serum of exosome-
immunized mice (Table 4.3). 
To further evaluate the potential involvement of lung cancer-associated 
keratin proteins in anti-lung tumor immunity evoked by ESC vaccines, the 
protein expression profile of LLC cells was examined by a proteomics approach. 
As expected, several keratins linked to lung tumorigenesis (keratin 7, 8, 16, 17 
and 18) were found to express in LLC cells (Table 4.3). These data suggest that 
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keratin members (8, 16, and 17) are candidate antigens responsible for 
initiating anti-lung tumor immunity through ADCC. 
 
 
Figure 4.8. Summary of identified antigens specific for vaccine-
generated antibodies. 
Antigens were identified by an affinity chromatography shotgun 
immunoproteomics strategy. (A) Numbers of antigens presented in the 
serum of mice immunized with cell-based vaccine. (B) Numbers of antigens 
presented in the serum of mice immunized with exosome-based vaccine. 
A 
B 
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Table 4.2. Keratin members recognized by antibodies in the serum of 
immunized mice. 
Keratin members recognized by antibodies in the serum of mice immunized 
with cell-based vaccine or exosome-based vaccine are listed. 
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Table 4.3. Keratin members as candidate antigens responsible for the 
vaccination efficacy of ES-D3- derived vaccines. 
The list includes lung cancer-associated keratin members identified in the 
serum of immunized mice or lung cancer cells (LLC). Those present in both 
the serum and LLC are marked in red. 
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DISSCUSION 
The generation of different types of tumors is a complex processes in which 
tumors acquire the ability of dynamic regulation and constituent cellular 
populations, recapitulating the complexity of organs or tissues [183]. For a long 
time, embryonic materials have been considered as a vaccine against cancers 
based on the similarities between embryos and tumors [18]. It has been found 
that some genes expressed in histologically poorly differentiated tumors cells 
are overexpressed in ESCs, and vice versa [85]. The identification of CSCs 
indicates that some tumor cells have the properties of stem cells to generate 
tumors [156]. In our study, parental ES-D3 cells display robust anchorage-
independent growth capability (Figure 4.2), a key signature of tumorigenesis 
that correlates with tumorigenic and metastatic potential in animals [171]. This 
suggests that the signaling transduction pathway(s) governing cell proliferation 
in ESCs is similar to that in neoplastic cells. Importantly, a decrease in the 
pluripotency of ESCs completely abolished their anchorage-independent 
growth potential, lending more support for the importance of ESC pluripotency 
in regulating the cellular phenotypes shared with tumor cells.  
Anti-tumor immunity is the most crucial factor in the prevention of 
tumorigenesis by the vaccination of ESCs. Furthermore, the similarity between 
ESC antigens and tumor antigens is considered to be responsible for inducing 
the immune responses against malignancy. In our study, vaccination with 
parental ESCs inhibited lung tumor development, whereas the differentiation of 
147 
 
ESCs suppressed the efficacy of the vaccine (Figure 4.3). As the protection 
against lung cancer conferred by ESC vaccination likely involves a number of 
shared antigens, it is conceivable that differentiation could decrease expression 
of tumor antigens on ESCs, leading to a reduction in cross-immunity against 
tumors. This is in agreement with the differentiation-evoked loss of tumor cell 
signatures in ESCs, such as anchorage-independent growth. However, the 
identities of specific cross-reactive antigens and their gene expression 
modulation need to be investigated in future studies.  
To explore the tumor-associated antigens shared between ES-D3 cells and 
malignant cells, we examined the comprehensive profiles of antigens specific 
for the antibodies induced by vaccines based on intact ES-D3 cells or 
exosomes of ES-D3 cells by an immunoproteomic approach (Table 4.2). This 
analysis reveals that ES-D3 cells and lung cancer cells share expression of a 
number of proteins implicated in tumorigenesis, which are candidate cross-
reactive antigens evoking anti-tumor immunity. Interestingly, none of the 
antibodies against tumor-antigens present in exosomes of ES-D3 cells (Table 
4.1) are enriched in the serum from immunized mice, suggesting that those 
antigens are likely involved in generating anti-lung cancer immunity through 
other mechanisms, such as promoting cytotoxic T cell responses against 
pulmonary malignancy. 
Our studies indicate the anti-tumor efficacies of both ESC cell-based or 
exosome-based vaccines were correlated with significantly enhanced T cell-
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mediated immune responses, including stronger Th1-mediated cytokine 
responses in splenic CD8+ T cells and higher CD8+ T/Tregs cell ratio in tumors 
[29], (Figures 2.10, 2.12). However, whether the humoral immune response 
mediated by antibodies also contributes to anti-cancer efficacy of ESC 
vaccination strategy remains unknown. Interestingly, a similar iPSC vaccine 
indeed produced antibodies specifically reactive to tumors cells [30]. Thus, it is 
possible that antibodies generated by ESC-based vaccine recognize the 
antigens on lung tumor cells to evoke ADCC-mediated anti-tumor immunity.  
A large portion of antigens identified by immunoproteomic analysis are 
keratin family members, which are proteins forming intermediate filaments in 
epithelial cells [182]. Notably, the expression of keratin proteins is crucial for 
uncontrolled proliferation of malignant cells of epithelial origin within anaplastic 
cancers. Keratins have been extensively used in clinical tumor diagnosis as 
immunohistochemical markers since 1980 [184]. Importantly, in the assessment 
of different types of cancer metastases, the expression patterns of keratin 
subtypes could be utilized to predict the origin of primary tumors [182]. Since it 
was discovered that keratins are expressed in all epithelial cells [185], several 
members of keratins, including keratin 7, 8, 16, 17, 18 and 19, have 
subsequently been identified as markers of lung cancer [186-188].  
Notably, keratin 8, 16, and 17 are among the lung cancer-associated keratin 
family members whose levels in serum are enhanced by both the cells-based 
vaccine as well as the exosome-based vaccine (Table 4.3). Since these keratin 
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proteins are also present in LLC cell lysate, they are likely to be the candidate 
antigens evoking immunity against LLC. Based on clinical research, the 
expression of keratin 8 is significantly higher in patients with non-small cell lung 
cancer (NSCLC) compared with small cell lung cancer (SCLC) patients [189]. 
It has been concluded that high expression of keratin 8 enhances tumor 
progression and indicates poor prognosis [189].  
Although keratin proteins form intermediate filaments are inside cells, 
emerging evidence indicate that some keratin family members are localized on 
cell surface. For instance, the presence of keratins 8, 18 and 19 were detected 
on the outer surface of human mammary carcinoma cells as well as in culture 
medium [190]. Similarly, keratin 8 is expressed at the surface of lung carcinoma 
cells, but not in normal epithelial cells [191]. Furthermore, fragments of keratin 
8 released by lung cancer cells were utilized as an indicator of tumor 
progression in clinical studies [192, 193]. Importantly, the interaction between 
keratin 8 and MHC class I was involved in CD8+ T cell activation in a lymph 
node metastatic carcinoma cell line [194]. It is conceivable that keratin 8 
molecules on lung tumor cell surface are recognized by specific antibodies 
generated by ESC-based vaccine, resulting in recruitment of effector immune 
cells and subsequent tumor cell apoptosis. 
As a member of the type I cytokeratins, keratin 16 has been found to 
associate with squamous differentiation [195]. A recent study demonstrates that 
keratin 16 possesses oncogenic activity to promote the tumorigenesis of lung 
150 
 
adenocarcinoma and is considered to be a predictive factor of poor patients 
prognosis [196, 197]. Accumulating studies indicate keratin 17 is 
overexpressed in a number of malignancies and plays an important role in the 
progression of tumors [197-200]. For example, it has been found that the mRNA 
level of keratin 17 is significantly elevated in lung carcinoma tissues compared 
with normal lung tissues. Markedly, metastasis and poor survival of lung cancer 
patients is correlated with high expression of keratin 17 [200]. Unlike keratin 8, 
the presence of keratins 16 and 17 on the surface of lung tumor cells remains 
unknown. More studies are needed to address how keratins 16 and 17 are 
involved in ESC vaccine-evoked ADCC. 
Overall, our studies reveal an important role of pluripotency of ESCs in anti-
lung cancer efficacy afforded by ESC-based vaccines. Furthermore, several 
keratin family members were identified as candidate cross-reactive antigens to 
confer immunity against lung cancer. Future research is warranted to elucidate 
the mechanisms of immunity against lung neoplastic diseases evoked by ESC-
based vaccination.  
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LIST OF ABBREVIATIONS 
 
ADCC 
AFP 
ALP 
ALT 
APCs 
BUN 
CAR 
CBC 
CEA 
CICs 
CISH 
CRC 
CSCs 
CSF 
CTA 
CTL 
CTLA 
 
antibody-dependent cellular cytotoxicity 
alpha fetoprotein 
alkaline phosphatase 
alanine transaminase 
antigen-presenting cells 
blood urea nitrogen 
chimeric antigen receptor 
complete blood count 
carcinoembryonic antigen 
cancer-initiating cells 
cytokine inducible SH2domain 
colorectal carcinoma 
cancer stem cells 
colony-stimulating factors 
cancer/testis antigen 
cytotoxic T lymphocyte 
cytotoxic T lymphocyte antigen
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DCs 
Dexosomes 
EF1a 
EGFR 
ESCs 
ES-exo/GM-CSF 
EVs 
FDA 
GM-CSF 
G-MDSCs 
HBV 
HPV 
HSPs 
IACUC 
ICAM-1 
IL 
INF 
iPSCs 
LDH 
LIF 
LLC 
MAGE 
dendritic cells 
dendritic cell-derived exosomes 
elongation factor-1a 
epidermal growth factor receptor 
embryonic stem cells 
ESC-derived exosomes bearing GM-CSF 
extracellular vesicles 
Food and Drug Administration 
granulocyte macrophage-colony stimulating factor 
granulocytic myeloid derived suppressor cells 
human hepatitis B virus 
human papilloma virus 
heat shock proteins 
institutional animal care and use committee 
intercellular cell-adhesion molecule-1 
interleukin 
interferon 
induced pluripotent stem cells 
lactate dehydrogenase 
leukemia inhibitory factor 
Lewis lung carcinoma 
melanoma-associated antigen 
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MDSCs 
MHC 
M-MDSCs 
MVBs 
NK 
NOD-SCID 
 
NSAID 
NSCLC 
PD-1 
PDI 
PD-L1 
PSA 
s.c. 
STAT5 
STR 
TAAs 
Tc 
TEM 
Texosomes 
TGF 
Th 
myeloid derived suppressor cells 
major histocompatibility complex 
monocytic myeloid derived suppressor cells 
multivesicular bodies 
natural killer 
non-obese diabetic severe combined 
immunodeficiency 
non-steroidal anti-inflammatory drug 
non-small cell lung carcinoma 
programmed cell death protein 1 
protein disulfide isomerase 
programmed cell death protein ligand 1 
prostate-specific antigen 
subcutaneous 
signal transducer and activator of transcription 5 
short tandem repeat 
tumor-associated antigens 
cytotoxic T cells 
transmission electron microscopy 
tumor-derived exosomes 
transforming growth factor 
T helper cell 
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TIL 
TLR2 
TLR4 
TNF-α 
TRAIL 
Tregs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tumor-infiltrating lymphocytes 
toll like receptor 2 
toll like receptor 4 
tumor necrosis factor alpha 
TNF-related apoptosis-inducing ligand 
T regulatory cells 
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